Professor Simon Rule

Biography

Qualifications

Bachelor of Medical Science with Honours 1984

Master of Philosophy 1986

Bachelor of Medicine 1987

Bachelor of Surgery 1987

Professional membership

Fellow of the Royal College of Physicians 2000

Fellow of the Royal College of Pathologists of Australasia 1994

Fellow of the Royal College of Pathologists 2006

Roles on external bodies

Member NCRN Lymphoma Committee (2000 – 2005, 2006 -)

Member Peninsula Comprehensive Local Research Network Board (2007 -)

Member European Mantle Cell Lymphoma Network (2007 -)

Member Peninsula Medical School R&D committee (2010 -)

Associate Medical Director for R&D Derriford Hospital (2010 -)

Member Cancer Research UK Clinical Trials Advisory Committee (2012 -)

Member Leukaemia and Lymphoma Research Clinical Trials Committee (2012 -)

Chair NCRN Low Grade NHL Committee (2013 -)

Research

Research interests

Clinical:

My clinical research is in non-Hodgkin’s lymphoma (NHL) and new drug development. Over the last 5 years I have been the Chief Investigator on 12 National studies and Principal Investigator on over 40 studies mostly involving NHL.

I have a particular interest in mantle cell non-Hodgkin’s lymphoma (MCL) and am regarded as the leading UK authority in this disease. I run a tertiary referral practice and see patients with this disease referred from all over the country in a weekly clinic. Within the UK I run all of the MCL trials. Over the last 10 years, 7 multi-centre trials have opened and 4 have recently completed. 4 of these studies were funded by Cancer Research UK, 2 others endorsed by CRUK and funded by industry The most recent studies are coordinated and run through the Plymouth CTU. Two large studies will open in 2015. One is a large bio-bank funded by Leukaemia Lymphoma Research exploring different disease characteristics of MCL. The other is a large randomised trial funded by Cancer Research UK looking at the use of ibrutinib as front line therapy in elderly patients with MCL randomised against standard immuno-chemotherapy. Both of these studies incorporate correlative science with a number of UK collaborators as well as in house laboratory research. With biological material stored in almost all patients this will be a unique repository for examining biological elements of the disease.

Laboratory:

My laboratory research is focussed on correlative science associated with samples collected within clinical trials. Currently we are exploring the mechanism of action lenalidomide, an immuno-modulatory drug based on a phase 2 single agent study run in Plymouth. Clinical responses correlate with changes in NK and T cell profiles and significant changes in a range of cytokines and chemokines. Gene expression analysis is currently being analysed on these samples. We have also described a new biomarker in this context (serum free light chains). This work is now being translated in vitro using cell lines and exploring the additional role of therapeutic antibodies to these agents. Lenalidomide affects cellular membranes and alters CD 20 configuration as seen on con-focal microscopy. This has significance if the drug is given in combination with an anti-CD20 monoclonal antibody and this work is informing a planned combination study. This has formed the basis of a recent PhD.

MCL is an aggressive form of non-Hodgkin’s lymphoma with an average survival of 3-4 years. As such it is common practice to treat the disease at diagnosis with intensive therapies. It has been my practice to observe patients at diagnosis who are asymptomatic and reserve treatment until symptoms evolve. A number of patients exhibit extremely indolent disease behaviour with some patients untreated for over 5 years. We have obtained a local grant to perform gene expression analysis on our most indolent patients compared with patients requiring immediate therapy. We observe a different gene expression signature which we are currently exploring further with the help of international collaborators.

The newer drugs that have activity in this disease (BTK, Pi3K and BCL-2 inhibitors)are being explored in the laboratory with cell line and patient samples with Dr Clare Hutchinson.

Research groups

Publications

Key publications

Key publications are highlighted

Journals

Articles

Bewicke-Copley F, Korfi K, Araf S, Hodkinson B, Kumar E, Cummin T, Ashton-Key M, Barrans SL, van Hoppe SJL & Burton C (2022) 'Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type Diffuse Large B Cell Lymphoma' Blood Advances , DOI Open access

Casulo C, Santoro A, Cartron G, Ando K, Munoz J, Le Gouill S, Izutsu K, Rule S, Lugtenburg P & Ruan J (2022) 'Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The <scp>FUSION NHL</scp> 001 trial' Cancer Reports , DOI Open access

Wang ML, Barrientos JC, Furman RR, Mei M, Barr PM, Choi MY, de Vos S, Kallam A, Patel K & Kipps TJ (2022) 'Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers' NEJM Evidence 1, (1) , DOI

Strati P, De Vos S, Ruan J, Maddocks KJ, Flowers CR, Rule S, Patel P, Xu Y, Wei H & Frigault MM (2021) 'Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study' Haematologica 106, (10) 2774-2778 , DOI Open access

Tam CS, Opat S, Simpson D, Cull G, Munoz J, Phillips TJ, Kim WS, Rule S, Atwal SK & Wei R (2021) 'Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma' Blood Advances 5, (12) 2577-2585 , DOI Open access

Rule S, Barreto WG, Briones J, Carella AM, Casasnovas O, Pocock C, Wendtner C-M, Zaja F, Robson S & MacGregor L (2021) 'Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study' Haematologica 107, (2) 500-509 , DOI Open access

Furman RR, Byrd JC, Owen RG, O’Brien SM, Brown JR, Hillmen P, Stephens DM, Chernyukhin N, Lezhava T & Hamdy AM (2021) 'Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies' Leukemia 35, (11) 3201-3211 , DOI

Jurczak W, Rule S, Townsend W, Tucker D, Sarholz B, Scheele J, Dyroff M, Gribben JG, Dlugosz-Danecka M & Zinzani PL (2021) 'Phase I, first-in-human trial of Bruton’s tyrosine kinase inhibitor M7583 in patients with B-cell malignancies' Leukemia & Lymphoma 62, (10) 2392-2399 , DOI

Dreyling M, Ghielmini M, Rule S, Salles G, Ladetto M, Tonino SH, Herfarth K, Seymour JF & Jerkeman M (2021) 'Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up' Annals of Oncology 32, (3) 298-308 , DOI

McCulloch R, Lewis D, Crosbie N, Eyre TA, Bolam S, Arasaretnam A, Creasey T, Goradia H, McMillan A & Dawi S (2021) 'Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real‐world analysis of outcomes in 211 patients' British Journal of Haematology 193, (2) 290-298 , DOI Open access

Le Gouill S, Morschhauser F, Chiron D, Bouabdallah K, Cartron G, Casasnovas O, Bodet-Milin C, Ragot S, Bossard C & Nadal N (2021) 'Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial' Blood 137, (7) 877-887 , DOI

Visco C, Di Rocco A, Evangelista A, Quaglia FM, Tisi MC, Morello L, Zilioli VR, Rusconi C, Hohaus S & Sciarra R (2021) 'Correction: Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study' Leukemia 35, (3) 932-932 , DOI

Morschhauser F, Dyer MJS, Walter HS, Danilov AV, Ysebaert L, Hodson DJ, Fegan C, Rule SA, Radford J & Cartron G (2020) 'Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma' Leukemia 35, (7) 2108-2113 Author Site , DOI Open access

Dimopoulos M, Sanz RG, Lee H-P, Trneny M, Varettoni M, Opat S, D'Sa S, Owen RG, Cull G & Mulligan S (2020) 'Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial' Blood Advances 4, (23) 6009-6018 , DOI Open access

McCulloch R, Eyre TA & Rule S (2020) 'What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?' Hematology/Oncology Clinics of North America 34, (5) 923-939 , DOI

McMillan AK, Phillips EH, Kirkwood AA, Barrans S, Burton C, Rule S, Patmore R, Pettengell R, Ardeshna KM & Lawrie A (2020) 'Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial' Annals of Oncology 31, (9) 1251-1259 , DOI Open access

Davies A, Barrans S, Burton C, Mercer K, Caddy J, Chinnery F, Day L, Fernando D, Ardeshna K & Collins G (2020) 'ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial' F1000Research 9, 941-941 , DOI Open access

Rule S & Johns S (2020) 'Advances in Classification and Treatment of Non-Hodgkin Lymphoma' The Cancer Journal 26, (4) 348-356 , DOI

McNamara C, Montoto S, Eyre TA, Ardeshna K, Burton C, Illidge T, Linton K, Rule S, Townsend W & Wong WL (2020) 'The investigation and management of follicular lymphoma' British Journal of Haematology 191, (3) 363-381 , DOI

Danilov AV, Herbaux C, Walter HS, Hillmen P, Rule SA, Kio EA, Karlin L, Dyer MJS, Mitra SS & Yi PC (2020) 'Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia' Clinical Cancer Research 26, (12) 2810-2818 , DOI

Tucker D, Morley N, MacLean P, Vandenberghe E, Booth S, Parisi L & Rule S (2020) 'The 5‐year follow‐up of a real‐world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed/refractory mantle cell lymphoma' British Journal of Haematology 192, (6) 1035-1038 , DOI

Phillips EH, Burton C, Kirkwood AA, Barrans S, Lawrie A, Rule S, Patmore R, Pettengell R, Ardeshna KM & Montoto S (2020) 'Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial' eJHaem 1, (1) 133-141 , DOI Open access

Bishton MJ, Rule S, Wilson W, Turner D, Patmore R, Clifton-Hadley L, McMillan A, Lush R & Haynes A (2020) 'The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival' British Journal of Haematology 190, (4) 545-554 , DOI

McCulloch R, Visco C, Eyre TA, Frewin R, Phillips N, Tucker DL, Quaglia FM, McMillan A, Lambert J & Crosbie N (2020) 'Efficacy of R‐BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy' British Journal of Haematology 189, (4) 684-688 , DOI

Owen RG, McCarthy H, Rule S, D'Sa S, Thomas SK, Tournilhac O, Forconi F, Kersten MJ, Zinzani PL & Iyengar S (2020) 'Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study' The Lancet Haematology 7, (2) e112-e121 , DOI

Morschhauser F, Machiels J-P, Salles G, Rottey S, Rule SAJ, Cunningham D, Peyrade F, Fruchart C, Arkenau H-T & Genvresse I (2020) 'On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors' Molecular Cancer Therapeutics 19, (2) 468-478 , DOI

Gribben J, Macintyre E, Sonneveld P, Doorduijn J, Gisselbrecht C, Jäger U, Le Gouill S, Rule S & Dreyling M (2020) 'Reducing Bureaucracy in Clinical Research: A Call for Action' HemaSphere 4, (2) e352-e352 , DOI Open access

Rule SA, Cartron G, Fegan C, Morschhauser F, Han L, Mitra S, Salles G & Dyer MJS (2019) 'Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)' Leukemia 34, (5) 1458-1461 , DOI Open access

Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn JK, Lamy T & Morschhauser F (2019) 'Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma' Leukemia 33, (11) 2762-2766 , DOI Open access

Eyre TA, Hildyard C, Hamblin A, Ali AS, Houlton A, Hopkins L, Royston D, Linton KM, Pettitt A & Rule S (2019) 'A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL' Hematological Oncology 37, (4) 352-359 , DOI

Jarvis MA, Hansen FA, Rosenke K, Haddock E, Rollinson C, Rule S, Sewell G, Hughes A & Feldmann H (2019) 'Evaluation of drugs for potential repurposing against COVID-19 using a tier-based scoring system' Antiviral Therapy , DOI Open access

Lavezzi SM, de Jong J, Neyens M, Cramer P, Demirkan F, Fraser G, Bartlett N, Dilhuydy M-S, Loscertales J & Avigdor A (2019) 'Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial' Pharmaceutical Research 36, (7) , DOI

Rule S & LeGouill S (2019) 'Bureaucracy is strangling clinical research' BMJ l1097-l1097 , DOI

Dreyling M, Klapper W & Rule S (2018) 'Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!' Blood 132, (26) 2722-2729 Author Site , DOI

Rule S, Cook G, Russell NH, Hunter A, Robinson S, Morley N, Sureda A, Patrick P, Clifton-Hadley L & Adedayo T (2018) 'Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma' British Journal of Haematology Author Site , DOI Open access

Brown JR, Moslehi J, Ewer MS, O'Brien SM, Ghia P, Cymbalista F, Shanafelt TD, Fraser G, Rule S & Coutre SE (2018) 'Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis' British Journal of Haematology 184, (4) 558-569 Author Site , DOI Open access

McCulloch R, Smith A, Crosbie N, Patmore R & Rule S (2018) 'Receiving treatment at a specialist centre confers an overall survival benefit for patients with mantle cell lymphoma' British Journal of Haematology 185, (5) 1002-1004 , DOI

Zaidi A, Dresman S, Charoltte B, Rule S & McCallum LMR (2018) 'Molecular signatures for CCN1, p21 and p27 in progressive mantle cell lymphoma' Journal of Cell Communication and Signaling Author Site Publisher Site , DOI Open access

Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, Hernández-Rivas J-Á, Qi K, Deshpande S & Parisi L (2018) 'Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis' Haematologica 104, (5) e211-e214 , DOI Open access

Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J & Gisselbrecht C (2018) 'Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies' The Lancet Haematology 5, (11) e563-e598 , DOI Open access

Rule S (2018) 'Bortezomib-based chemotherapy in mantle cell lymphoma' Lancet Oncology 19, (11) 1419-1421 Author Site , DOI

Rule SAJ (2018) 'Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine and rituximab in 1 relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma' Leukemia , DOI

Rule S & Chen RW (2018) 'New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?' Expert Review of Hematology 11, (9) Author Site , DOI Open access

McKay P, Leach M, Jackson B, Robinson S & Rule SAJ (2018) 'A British Society for Haematology Good Practice Paper on the Diagnosis and Investigation of Patients with Mantle Cell Lymphoma' British Journal of Haematology 181, (1) 63-70 , DOI Open access

Rule SAJ, McKay P, Leach M, Jackson R & Robinson S (2018) 'Guideline for the Management of Mantle Cell Lymphoma' British Journal of Haematology , DOI Open access

Parrott M & Rule S (2018) 'Does maintenance therapy have a role in mantle cell lymphoma treatment?' Expert Review of Hematology 11, (4) 285-292 , DOI

Rule S (2018) 'Can we improve on ibrutinib in mantle cell lymphoma?' The Lancet Haematology 5, (3) e98-e99 , DOI

Rule S, Jurczak W, Jerkeman M, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M & Hess G (2018) 'Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study' Leukemia Author Site , DOI Open access

Cramer P, Fraser G, Santucci-Silva R, Grosicki S, Dilhuydy M-S, Janssens A, Loscertales J, Rule S, Goy A & Traina S (2018) 'Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study' Leukemia and Lymphoma 59, (9) 2075-2084 Author Site , DOI Open access

Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T & Morschhauser F (2017) 'Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial' The Lancet 391, (10121) 659-667 Author Site , DOI Open access

Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U & Ladetto M (2017) 'Correction to: Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up' Annals of Oncology 28, (12) 3109-3109 , DOI

Le Gouill S, Dreyling M, Caballero MD, Andre M, Doorduijn J, Jurczak W, Jerkeman M, Ghia P, Zinzani P-L & Da Silva MG (2017) 'Is Good Clinical Practice Becoming Poor Clinical Care?' HemaSphere 1, (1) e4-e4 , DOI Open access

Arcaini L, Lamy T, Walewski J, Belada D, Mayer J, Radford J, Jurczak W, Morschhauser F, Alexeeva J & Rule S (2017) 'Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma' British Journal of Haematology 180, (2) 224-235 , DOI Open access

Wang M, Schuster SJ, Phillips T, Lossos IS, Goy A, Rule S, Hamadani M, Ghosh N, Reeder CB & Barnett E (2017) 'Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)' Journal of Hematology & Oncology 10, (1) , DOI Open access

McCulloch R & Rule S (2017) 'What is the optimal initial management of the younger mantle cell lymphoma patient?' Best Practice and Research: Clinical Haematology 31, (1) 90-98 , DOI

Parrott M, Rule SAJ, Kelleher M & Wilson J (2017) 'A systematic review of treatments for relapsed/refractory mantle cell lymphoma' Clinical Lymphoma, Myeloma and Leukemia , DOI Open access

Davies A, Berge C, Boehnke A, Dadabhoy A, Lugtenburg P, Rule S, Rummel M, McIntyre C, Smith R & Badoux X (2017) 'Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development' Advances in Therapy 34, (10) 2210-2231 , DOI Open access

Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, Cavazos N, Liu B, Yang S & Clow F (2017) 'Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies' British Journal of Haematology , DOI Open access

Brown JR, Moslehi J, O’Brien S, Ghia P, Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S & Kipps TJ (2017) 'Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials' Haematologica 102, (10) 1796-1805 , DOI Open access

Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J & Pfreunschuh M (2017) 'International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)' Annals of Oncology 28, (7) 1436-1447 , DOI Open access

Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, Shpilberg O, Walewski J & Ladetto M (2017) 'Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up' Annals of Oncology 28, iv62-iv71 , DOI

Pratt G, Yap C, Oldreive C, Slade D, Bishop R, Griffiths M, Dyer MJS, Fegan C, Oscier D & Pettitt A (2017) 'A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma' British Journal of Haematology 182, (3) 429-433 , DOI

Hess G, Rule S, Jurczak W, Jerkeman M, Santucci Silva R, Rusconi C, Caballero D, Joao C, Witzens-Harig M & Bence-Bruckler I (2017) 'Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus' Leukemia & Lymphoma 58, (12) 2824-2832 , DOI

Burrows SH, Akinbobuyi O, Rule S & Crosbie N (2017) 'Subcutaneous rituximab can be safely administered without pre-medication' British Journal of Haematology 181, (6) 836-837 , DOI

Walter HS, Jayne S, Rule SA, Cartron G, Morschhauser F, Macip S, Karlin L, Jones C, Herbaux C & Quittet P (2017) 'Long-term follow-up of patients with CLL treated with the selective Bruton’s tyrosine kinase inhibitor ONO/GS-4059' Blood 129, (20) 2808-2810 , DOI

Tucker D & Rule S (2017) 'Novel agents in mantle cell lymphoma' Expert Review of Anticancer Therapy 17, (6) 491-506 , DOI

Czuczman MS, Trnený M, Davies A, Rule S, Linton KM, Wagner-Johnston N, Gascoyne RD, Slack GW, Brousset P & Eberhard DA (2017) 'A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma' Clinical Cancer Research 23, (15) 4127-4137 , DOI

Grigg A, Dyer MJS, Díaz MG, Dreyling M, Rule S, Lei G, Knapp A, Wassner-Fritsch E & Marlton P (2016) 'Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma' Haematologica 102, (4) 765-772 , DOI Open access

Rule S (2016) 'Frontline therapy and role of high-dose consolidation in mantle cell lymphoma' Hematology 2016, (1) 419-424 , DOI

Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U & Ladetto M (2016) 'Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up' Annals of Oncology 27, v83-v90 , DOI

Tucker DL, Naylor G, Kruger A, Hamilton MS, Follows G & Rule SA (2016) 'Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom' British Journal of Haematology , DOI Open access

Tucker DL, Mihailescu L, Riordan R & Rule S (2016) 'Remineralization of lytic bone disease in a patient with small lymphocytic lymphoma using ibrutinib' British Journal of Haematology , DOI

Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, Rule S, Advani R, Iberri D & Phillips T (2016) 'Postibrutinib outcomes in patients with mantle cell lymphoma' Blood 127, (12) 1559-1563 , DOI

Trnený M, Lamy T, Walewski J, Belada D, Mayer J, Radford J, Jurczak W, Morschhauser F, Alexeeva J & Rule S (2016) 'Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial' The Lancet Oncology 17, (3) 319-331 , DOI

Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J & Bartlett NL (2016) 'Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study' The Lancet Oncology 17, (2) 200-211 , DOI

Tucker DL & Rule SA (2016) 'Ibrutinib for mantle cell lymphoma' Future Oncology 12, (4) 477-491 , DOI

Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, Offner F, Caballero D, Joao C & Witzens-Harig M (2016) 'Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study' The Lancet 387, (10020) 770-778 , DOI

Walter HS, Rule SA, Dyer MJS, Karlin L, Jones C, Cazin B, Quittet P, Shah N, Hutchinson CV & Honda H (2016) 'A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies' Blood 127, (4) 411-419 , DOI

Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Dohner H, de Wit TD, Eichinger S, Fibbe W & Green T (2016) 'The European Hematology Association Roadmap for European Hematology Research: a consensus document' Haematologica 101, (2) 115-208 , DOI

Rule S (2016) 'A new standard of care for mantle cell lymphoma?' The Lancet Oncology 17, (1) 5-6 , DOI

Rule S, Smith P, Johnson PWM, Bolam S, Follows G, Gambell J, Hillmen P, Jack A, Johnson S & Kirkwood AA (2015) 'The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial' Haematologica 101, (2) 235-240 , DOI

Dreyling M, Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH & Romaguera JE (2015) 'Long-term safety and efficacy of single-agent lbrutinib in patients with relapsed or refractory mantle cell lymphoma: Updated results of an international, multicenter, open-label phase 2 study' Oncology Research and Treatment 38, 18-19 Author Site

Cramer P, Chanan-Khan A, Fraser G, Demirkan F, Silva RS, Pylypenko H, Grosicki S, Janssens A, Pristupa A & Goy A (2015) 'Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): safety analysis in the HELIOS trial' LEUKEMIA & LYMPHOMA 56, 93-94 Author Site

Fraser G, Chanan-Khan A, Cramer P, Demirkan F, Silva RS, Pylypenko H, Grosicki S, Janssens A, Pristupa A & Goy A (2015) 'Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): subgroup efficacy analyses from the HELIOS trial' LEUKEMIA & LYMPHOMA 56, 98-100 Author Site

Chanan-Khan A, Fraser G, Cramer P, Demirkan F, Silva RS, Pylypenko H, Grosicki S, Janssens A, Pristupa A & Goy A (2015) 'Ibrutinib combined with bendamustine/rituximab (BR) in previously treated small lymphocytic lymphoma (SLL): analysis of patients in the HELIOS trial' LEUKEMIA & LYMPHOMA 56, 92-93 Author Site

Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE & Williams ME (2015) 'Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results' Blood 126, (6) 739-745 , DOI

Jones GL, Will A, Jackson GH, Webb NJ & Rule S (2015) 'Evolving concepts in tumour lysis syndrome management - response to Ayed et al' British Journal of Haematology 173, (3) 486-487 , DOI

Furtado M, Clarke K, Medd P, Hunter H & Rule S (2015) 'The use of Bruton's tyrosine kinase inhibition as a bridging strategy to successful allogeneic stem cell transplant in relapsed mantle cell lymphoma' Leukemia & Lymphoma 57, (2) 461-462 , DOI

Rule S & Tucker D (2015) 'A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia' Therapeutics and Clinical Risk Management 979-979 , DOI

Chanan-Khan AAA, Cramer P, Demirkan F, Fraser G, Silva RS, Pylypenko H, Grosicki S, Janssens A, Pristupa A & Mayer J (2015) 'Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study' Journal of Clinical Oncology 33, (15_suppl) LBA7005-LBA7005 , DOI

Trneny M, Lamy T, Walewski JA, Belada D, Mayer J, Radford JA, Jurczak W, Morschhauser F, Alexeeva J & Rule S (2015) 'Subgroup analysis of the phase II randomized MCL-002 (SPRINT) study of lenalidomide vs investigator’s choice in relapsed/refractory mantle cell lymphoma' Journal of Clinical Oncology 33, (15_suppl) 8547-8547 , DOI

Rule S, Goy A, Martin P, Ramchandren R, Alexeeva J, Popat R, Avivi I, Advani R, Le Gouill S & Horowitz N (2015) 'Ibrutinib for the treatment of Mantle Cell Lymphoma (MCL): evaluating the correlation between patient-reported outcomes and durability of response in a Phase 2 study' Value in Health 18, (3) A300-A301 , DOI

Jones GL, Will A, Jackson GH, Webb NJA & Rule S (2015) 'Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology' British Journal of Haematology 169, (5) 661-671 , DOI

Tucker DL, Rockett M, Hasan M, Poplar S & Rule SA (2015) 'Does transcutaneous electrical nerve stimulation (TENS) alleviate the pain experienced during bone marrow sampling in addition to standard techniques? A randomised, double-blinded, controlled trial' Journal of Clinical Pathology 68, (6) 479-483 , DOI

Furtado M, Wang ML, Munneke B, McGreivy J, Beaupre DM & Rule S (2015) 'Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma' British Journal of Haematology 170, (1) 131-134 , DOI

Campo E & Rule S (2015) 'Mantle cell lymphoma: evolving management strategies' Blood 125, (1) 48-55 , DOI

Furtado M & Rule S (2015) 'New Treatment Options in Mantle Cell Lymphoma' European Oncology & Haematology 11, (2) 134-134 , DOI

Balasubramanian S, Schaffer M, Deraedt W, Davis C, Stepanchick E, Aquino R, Yuan Z, Kranenburg B, Avivi I & Dreyling M (2014) 'Mutational Analysis of Patients with Primary Resistance to Single-Agent Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)' Blood 124, (21) 78-78 , DOI

Wang M, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani R, Romaguera JE & Williams ME (2014) 'Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study' Blood 124, (21) 4453-4453 , DOI

Rule S (2014) 'Response to the letter from Gozzettiet al.entitled: “Oral low-dose fludarabine and cyclophosphamide with rituximab as initial treatment for elderly patients with chronic lymphoproliferative disorders”' Leukemia & Lymphoma 56, (6) 1918-1918 , DOI

Shah N, Tam C, Seymour JF & Rule S (2014) 'How applicable is fludarabine, cyclophosphamide and rituximab to the elderly?' Leukemia & Lymphoma 56, (6) 1599-1610 , DOI

Rule S, Briones J, Smith R, Theodore OC, Ngoh CA, Osborne S, Capochiani E & Rummel M (2014) 'Preference for Rituximab Subcutaneous (Sc) and Intravenous (Iv) Among Patients With Cd20+ Non-Hodgkin's Lymphoma (Nhl) Completing the Rasq Measure In Randomized Phase Iii Studies Prefmab and Mabcute' Value in Health 17, (7) A537-A537 , DOI

Stilgenbauer S, Rule S, Wang ML, Martin P, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera J & Williams M (2014) 'Updated phase 2 safety analysis of prevalence of infection, diarrhea, and bleeding with ibrutinib over time in previously treated mantle cell lymphoma' ONCOLOGY RESEARCH AND TREATMENT 37, 34-35 Author Site

Dreyling M, Geisler C, Hermine O, Kluin-Nelemans HC, Le Gouill S, Rule S, Shpilberg O, Walewski J & Ladetto M (2014) 'Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up' Annals of Oncology 25, iii83-iii92 , DOI

Shah N, Hutchinson C & Rule S (2014) 'Ibrutinib for the treatment of mantle cell lymphoma' Expert Review of Hematology 7, (5) 521-531 , DOI

Furtado M, Johnson R, Kruger A, Turner D & Rule S (2014) 'Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma' British Journal of Haematology 168, (1) 55-62 , DOI

Dreyling M, Amador V, Callanan M, Jerkeman M, Le Gouill S, Pott C, Rule S & Zaja F (2014) 'Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network' Leukemia & Lymphoma 56, (4) 866-876 , DOI

Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW & Byrd JC (2014) 'A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed ch' British Journal of Haematology 167, (4) 466-477 , DOI

Robinson S, Dreger P, Caballero D, Corradini P, Geisler C, Ghielmini M, Le Gouill S, Kimby E, Rule S & Vitolo U (2014) 'The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma' Leukemia 29, (2) 464-473 , DOI

Rule S, Collins GP & Samanta K (2014) 'Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom' Journal of Medical Economics 17, (7) 459-468 , DOI

Furtado M, Dyer MJS, Johnson R, Berrow M & Rule S (2014) 'Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma - a phase II trial' British Journal of Haematology 165, (4) 575-578 , DOI

Shah N & Rule S (2014) 'Management perspective for mantle cell lymphoma' International Journal of Hematologic Oncology 3, (1) 31-40 , DOI

Rule S, Shah N, Salles GA, Karlin L, Morschhauser F, Terriou L, Dyer MJS, Hutchinson C, Fegan C & Cartron G (2013) 'A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory B-Cell Lymphoma' Blood 122, (21) 4397-4397 , DOI

Rule S, Briones J, Carella AM, Casasnovas O, Barreto WG, Pocock C, Osborne S, Smith R & Zaja F (2013) 'A Randomized Comparison Of Maintenance Therapy With Subcutaneous Rituximab For 2 Years Versus Until Progression In Patients With Indolent Non-Hodgkin’s Lymphoma: Interim Safety Data From The Mabcute Study' Blood 122, (21) 3052-3052 , DOI

McMillan A, Ardeshna KM, Gambell J, Jack A, Kirkwood A, Laurie A, Montoto S, Paneesha S, Rule S & Patmore R (2013) 'Rituximab and CODOX-M / IVAC Without Stem Cell Transplantation For Poor Risk Diffuse Large B Cell Lymphoma (IPI3-5) and Burkitts Lymphoma Is Feasible and Gives a High Response Rate: Preliminary Results Of a Phase 2 UK National Cancer Research Institute Trial' Blood 122, (21) 4348-4348 , DOI

Robinson SP, Corradini P, Dreger P, Caballero D, Geisler CH, Ghielmini M, Le Gouill S, Kimby E, Rule S & Vitolo U (2013) 'The EBMT Lymphoma Working Party-European Mantle Cell Lymphoma Network Consensus Project On The Role Of Autologous and Allogeneic Stem Cell Transplantation In Mantle Cell Lymphoma: Recommendations Applying The Delphi Procedure' Blood 122, (21) 3405-3405 , DOI

Wang ML, Rule SAJ, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Ranjana H & Romaquera JE (2013) 'Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma' New England Journal of Medicine 369, (6) 507-516 , DOI

Jurczak W, Rule S, Martin P, Auer R, Kahl BS, Giza A, Jachimczak B, Advani RH, Romaguera J & Williams M (2013) 'Inhibitor kinazy Brutona u chorych z nawrotowym lub opornym na leczenie chłoniakiem z komórek płaszcza – wyniki międzynarodowego, wieloośrodkowego, badania II fazy z ibrutynibem (PCI-32765) – EHA Encore' Acta Haematologica Polonica 44, (3) 314-318 , DOI

Wang M, Gordon LI, Rule S, Goy A, Hermine O, Rizo A, Zhuang SH & Dreyling MH (2013) 'A phase III study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed mantle cell lymphoma (MCL)' Journal of Clinical Oncology 31, (15_suppl) TPS8613-TPS8613 , DOI

Coiffier B, Li W, Henitz ED, Karkera JD, Favis R, Gaffney D, Shapiro A, Theocharous P, Elsayed YA & van de Velde H (2013) 'Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab' Clin Cancer Res 19, (9) 2551-2561 Author Site , DOI

Burt C, Roddari J, Mindos T, Furtado M, Rule S & McCallum L (2013) 'CCN1 modulates cell growth in aggressive mantle cell lymphoma' BRITISH JOURNAL OF HAEMATOLOGY 161, 44-44 Author Site

Shah N, Furtado M, Eve H & Rule S (2013) 'Natural killer cells and their clinical correlation in mantle cell lymphoma (MCL)' BRITISH JOURNAL OF HAEMATOLOGY 161, 55-55 Author Site

Rule S, Furtado M, Eve H, Johnson R, Kruger A, Turner D & Bullard S (2013) 'The addition of bortezomib to standard dose CHOP chemotherapy significantly improves survival in relapsed mantle cell lymphoma - final analysis of a randomised UK NCRN trial' BRITISH JOURNAL OF HAEMATOLOGY 161, 5-5 Author Site

Leblond V, Johnson S, Chevret S, Copplestone A, Rule S, Tournilhac O, Seymour JF, Patmore RD, Wright D & Morel P (2013) 'Results of a Randomized Trial of Chlorambucil Versus Fludarabine for Patients With Untreated Waldenström Macroglobulinemia, Marginal Zone Lymphoma, or Lymphoplasmacytic Lymphoma' Journal of Clinical Oncology 31, (3) 301-307 , DOI

Furtado M, Shah N, Levoguer A, Harding S & Rule S (2013) 'Abnormal serum free light chain ratio predicts poor overall survival in mantle cell lymphoma' Br J Haematol 160, (1) 63-69 Author Site , DOI

McKay P, Leach M, Jackson R, Cook G & Rule S (2012) 'Guidelines for the investigation and management of mantle cell lymphoma' BRITISH JOURNAL OF HAEMATOLOGY 159, (4) 405-426 Author Site , DOI

Eve HE, Carey S, Helse CC, Richardson SJ, Mamidipudi V, Shi T, Radford JA, Auer RL, Bullard SH & Rule SA (2012) 'Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences' British Journal of Haematology 159, (2) 154-163 , DOI

Wright TM, Rule S, Liu H, Du M-Q & Smith MEF (2012) 'Extranodal marginal zone lymphoma of the uterine corpus' LEUKEMIA & LYMPHOMA 53, (9) 1831-1834 Author Site , DOI

Eve HE, Carey S, Richardson SJ, Heise CC, Mamidipudi V, Shi T, Radford JA, Auer RL, Bullard SH & Rule SAJ (2012) 'Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences' British Journal of Haematology 159, (2) 154-163 , DOI

Farrell K & Rule S (2012) 'Mantle-cell lymphoma in the elderly: is it time to CHOP and change?' Leukemia & Lymphoma 53, (10) 1855-1856 , DOI

Furtado M & Rule S (2012) 'Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin's Lymphoma: Focus on Brentuximab Vedotin' Clin Med Insights Oncol 6, 31-39 Author Site , DOI

Dreyling M, Kluin-Nelemans HC, Bea S, Hartmann E, Salaverria I, Hutter G, Perez-Galan P, Roue G, Pott C & Le Gouill S (2011) 'Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network' LEUKEMIA & LYMPHOMA 52, (12) 2226-2236 Author Site , DOI

Coiffier B, Li W, Henitz ED, Karkera JD, Favis R, Gaffney D, Shapiro A, Theocharous P, Elsayed YA & van de Velde H (2011) 'Identification of Patient Subgroups Demonstrating Longer Progression-Free Survival (PFS) Benefit with Bortezomib-Rituximab Versus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma (FL): Biomarker Analyses of the Phase 3 LYM3001 Study' Blood 118, (21) 265-265 , DOI

Wang L, Martin P, Blum KA, Kahl BS, Maeda LS, Advani R, Williams ME, Rule S, Rodriguez S & Pang C-F (2011) 'The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial' Blood 118, (21) 442-442 , DOI

Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Walewski J & de Vos S (2011) 'Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial' LANCET ONCOLOGY 12, (8) 773-784 Author Site , DOI

Furtado M & Rule S (2011) 'Indolent mantle cell lymphoma' HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 96, (8) 1086-1088 Author Site , DOI

Rule SAJ, Poplar S, Evans PAS, O'Connor SJM & Owen RG (2011) 'Indolent Mantle-Cell Lymphoma: Immunoglobulin Variable Region Heavy Chain Sequence Analysis Reveals Evidence of Disease 10 Years Prior to Symptomatic Clinical Presentation' Journal of Clinical Oncology 29, (15) e437-e439 , DOI

Rule S (2011) 'Velcade combinations in mantle cell lymphoma: are we learning anything?' Leuk Lymphoma 52, (4) 545-547 Author Site , DOI

Hellmann A, Rule S, Walewski J, Shpilberg O, Feng H, van de Velde H, Patel H, Skee DM, Girgis S & Louw VJ (2011) 'Effect of Cytochrome P450 3A4 Inducers on the Pharmacokinetic, Pharmacodynamic and Safety Profiles of Bortezomib in Patients with Multiple Myeloma or Non-Hodgkin's Lymphoma' CLINICAL PHARMACOKINETICS 50, (12) 781-791 Author Site , DOI

Coiffier B, Osmanov E, Hong X, Scheliga A, Mayer J, Offner FC, Rule SA, Teixeira A, Walewski JA & Crump M (2010) 'A Phase 3 Trial Comparing Bortezomib Plus Rituximab with Rituximab Alone In Patients with Relapsed, Rituximab-Naive or -Sensitive, Follicular Lymphoma' Blood 116, (21) 857-857 , DOI

Hellmann A, Rule SA, Walewski J, Shpilberg O, Feng H, van de Velde H, Patel H, Skee DM, Girgis S & Louw V (2010) 'Effect of the Cytochrome P450 3A4 Inducers, Rifampicin and Dexamethasone, on the Pharmacokinetic, Pharmacodynamic and Safety Profile of Bortezomib In Patients with Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL)' Blood 116, (21) 3983-3983 , DOI

Agathocleous A, Rohatiner A, Rule S, Hunter H, Kerr JP, Neeson SM, Matthews J, Strauss S, Montoto S & Johnson P (2010) 'Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia' Br J Haematol 151, (4) 346-353 Author Site , DOI

Cook G, Smith GM, Kirkland K, Lee J, Pearce R, Thomson K, Morris E, Orchard K, Rule S & Russell N (2010) 'Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study of the British Society for Blood and Marrow Transplantation' BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 16, (10) 1419-1427 Author Site , DOI

Eve HE & Rule SAJ (2010) 'Lenalidomide-induced tumour flare reaction in mantle cell lymphoma' British Journal of Haematology 151, (4) 410-412 , DOI

Rule S (2010) 'Everolimus in relapsed Hodgkin's lymphoma: something exciting or a case of caveat mTOR?' Am J Hematol 85, (5) 313-314 Author Site , DOI

Matthey F, Parker A, Rule SAJ, Wimperis JZ, Ardeshna KM, Bird JM, Cullis J, Lyttelton MPA, McMillan A & Jackson GH (2010) 'Facilities for the treatment of adults with haematological malignancies - 'Levels of Care': BCSH Haemato-Oncology Task Force 2009' HEMATOLOGY 15, (2) 63-69 Author Site , DOI

Eve HE & Rule SAJ (2010) 'Autoimmune haemolytic anaemia associated with mantle cell lymphoma' International Journal of Hematology 91, (2) 322-325 , DOI

Richardson SJ, Eve HE, Copplestone JA, Dyer MJ & Rule SAJ (2010) 'Activity of thalidomide and lenalidomide in mantle cell lymphoma' Acta Haematol 123, (1) 21-29 Author Site , DOI

Eve HE, Furtado MV, Hamon MD & Rule SAJ (2009) 'Time to Treatment Does Not Influence Overall Survival in Newly Diagnosed Mantle-Cell Lymphoma' Journal of Clinical Oncology 27, (32) e189-e190 , DOI

Rule S, Smith P, Qian W, Gambell J, Curtis N, Johnson P & Linch D (2009) 'Application of the mantle international prognostic index (MIPI) to patients with mantle cell lymphoma treated with fludarabine/cyclophosphamide: Results from a UK NCRI Lymphoma Group study' Journal of Clinical Oncology 27, (15_suppl) 8555-8555 , DOI

Pace E, Dennison S, Morris J, Barton A, Pritchard C & Rule SAJ (2009) 'Chemotherapy in the community: what do patients want?' Eur J Cancer Care (Engl) 18, (2) 209-215 Author Site , DOI

Furtado MV & Rule SAJ (2009) 'Validation of the mantle cell lymphoma international prognostic index (MIPI) in a non selected population of patients' BRITISH JOURNAL OF HAEMATOLOGY 145, 14-14 Author Site

Eve HE, Seymour JF & Rule SAJ (2009) 'Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide±rituximab' Leukemia & Lymphoma 50, (3) 463-465 , DOI

Eve HE, Gambell J, Smith P, Qian W & Rule SAJ (2009) 'The simplified mantle cell lymphoma international prognostic index predicts overall survival but not progression-free survival in patients with mantle cell lymphoma treated with fludarabine and cyclophosphamide±rituximab: results of a randomized phase II trial' Leukemia & Lymphoma 50, (10) 1709-1711 , DOI

Eve HE, Linch D, Qian W, Ross M, Seymour JF, Smith P, Stevens L & Rule SAJ (2009) 'Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study' Leukemia & Lymphoma 50, (2) 211-215 , DOI

Pettengell R, Donatti C, Hoskin P, Poynton C, Kettle PJ, Hancock B, Johnson S, Dyer MJS, Rule S & Walker M (2008) 'The impact of follicular lymphoma on health-related quality of life' ANNALS OF ONCOLOGY 19, (3) 570-576 Author Site , DOI

Furtado M & Rule S (2008) 'Bortezomib-associated tumor lysis syndrome in multiple myeloma' LEUKEMIA & LYMPHOMA 49, (12) 2380-2382 Author Site , DOI

Sleigh KA, Smith MEF & Rule SAJ (2008) 'Cardiac involvement with mycosis fungoides: Could this explain alemtuzumab toxicity?' Leukemia & Lymphoma 49, (10) 2022-2024 , DOI

Agathocleous A, Rule S, Johnson P, Radford JA, Lafon N, Hunter H, Kerr JP, Neeson SM, Matthews J & Strauss S (2007) 'Preliminary Results of a Phase I/II Study of Weekly or Twice Weekly Bortezomib in Combination with Rituximab, in Patients with Follicular Lymphoma, Mantle Cell Lymphoma and Waldenström’s Macroglobulinaemia' Blood 110, (11) 2559-2559 , DOI

Morschhauser F, Illidge T, Huglo D, Martinelli G, Paganelli G, Zinzani PL, Rule S, Liberati AM, Milpied N & Hess G (2007) 'Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphorna not appropriate for autologous stem-cell transplantation' BLOOD 110, (1) 54-58 Author Site , DOI

Cairo MS, Cornelis M, Baruchel A, Bosly A, Cheson B, Pui C, Ribera JM, Rule S, Younes A & Coiffier B (2007) 'Risk assessment and medical decision model for prophylaxis and treatment of hyperuricemia and tumor lysis syndrome (TLS): International expert panel analysis' Journal of Clinical Oncology 25, (18_suppl) 17006-17006 , DOI

Richardson SJ, Widmer M, Zajicek J & Rule SA (2007) 'Physiological doses of cannabinoids do not adversely affect MCL viability' Leukemia & Lymphoma 48, (9) 1855-1857 , DOI

Joshi S, Jeffery J, Rule S & Ayling R (2006) 'Hypokalaemia in acute myeloid leukaemia - A paraneoplastic phenomenon?' HAEMA 9, (5) 691-692

Cherian G, Thomas DW & Rule SAJ (2006) 'The efficacy of low dose thalidomide in refractory/relapsed myeloma - a retrospective audit' LEUKEMIA & LYMPHOMA 47, (11) 2409-2411 Author Site , DOI

Dasgupta RK, Rule S, Johnson P, Davies J, Burnett A, Poynton C, Wilson K, Smith GM, Jackson G & Richardson C (2006) 'Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect' Bone Marrow Transplant 37, (5) 455-461 Author Site , DOI

Thomas DW, Owen RG, Johnson SAN, Hillmen P, Seymour JF, Wolf MM & Rule SAJ (2005) 'Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP' Leukemia & Lymphoma 46, (4) 549-552 , DOI

Harries LW, Wickham CL, Evans JC, Rule SA, Joyner MV & Ellard S (2004) 'Analysis of haematopoietic chimaerism by quantitative real-time polymerase chain reaction' Bone Marrow Transplantation 35, (3) 283-290 , DOI

Rule S (2004) 'Managing cancer-related skeletal events with bisphosphonates' Hosp Med 65, (6) 355-360 Author Site , DOI

Snowden JA, Passweg J, Moore JJ, Milliken S, Cannell P, Van Laar JM, Verburg R, Szer J, Taylor K & Joske D (2004) 'Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: A report from the EBMT and ABMTR' JOURNAL OF RHEUMATOLOGY 31, (3) 482-488 Author Site

Pagliuca A, Carrington PA, Pettengell R, Rule S, Keidan J & Haematology BCS (2003) 'Guidelines on the use of colony-stimulating factors in haematological malignancies' BRITISH JOURNAL OF HAEMATOLOGY 123, (1) 22-33 Author Site , DOI

Duckworth AW & Rule SAJ (2003) 'The use of ‘touchdown’ polymerase chain reaction increases the sensitivity and specificity of t(11;14)(q13;q32) detection in patients with mantle cell lymphoma' British Journal of Haematology 121, (6) 952-953 , DOI

Rule S & Copplestone A (2003) 'Ethics of large clinical trials in rapidly lethal diseases' The Lancet 361, (9365) 1297-1297 , DOI

Mawson AR (2003) 'Ethics of large clinical trials in rapidly lethal diseases' The Lancet 361, (9365) 1296-1296 , DOI

Rule SAJ, O'Brien SG & Crossman LC (2002) 'Managing cutaneous reactions to imatinib therapy' Blood 100, (9) 3434-3434 , DOI

O'Brien SG & Rule SAJ (2002) 'Position paper on imatinib mesylate in chronic myeloid leukaemia*' British Journal of Haematology 119, (1) 268-272 , DOI

Moore J, Brooks P, Milliken S, Biggs J, Ma D, Handel M, Cannell P, Will R, Rule S & Joske D (2002) 'A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis' Arthritis & Rheumatism 46, (9) 2301-2309 , DOI

Monk SE, Duckworth AW, Farrugia J, Copplestone JA & Rule SAJ (2002) 'Allelic Discrimination of Factor V Leiden Using the GeneAmp® 5700 Sequence Detection System' Thrombosis and Haemostasis 88, (12) 1071-1072 , DOI

Boogaerts M (2001) 'Intravenous and Oral Itraconazole versus Intravenous Amphotericin B Deoxycholate as Empirical Antifungal Therapy for Persistent Fever in Neutropenic Patients with Cancer Who Are Receiving Broad-Spectrum Antibacterial Therapy' Annals of Internal Medicine 135, (6) 412-412 , DOI

Rule S, Poirer V & Singer C (2001) 'Management of acute myeloid leukaemia' Clinical Medicine 1, (4) 312-316

Rule S (2001) 'Non-Hodgkin's lymphoma' Clin Med (Lond) 1, (5) 362-364 Author Site , DOI

Rule S, Poirer V & Singer C (2001) 'Management of acute myeloid leukaemia. A regional audit in the south and west of the United Kingdom' Clin Med (Lond) 1, (4) 313-316 Author Site , DOI

Savage DG, I Rule SA, Tighe M, Garrett TJ, Oster WM, Lee RT, Ruiz J, Heitjan D, Keohan ML & Flamm M (2000) 'Gemcitabine for relapsed or resistant lymphoma' Annals of Oncology 11, (5) 595-598 , DOI

Child JA, Johnson SA, Rule S, Smith GM, Morgan GJ, Johnson PWM, Prentice AG, Tollerfield SM & Wareham E (2000) 'FLUDAP: Salvage Chemotherapy for Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma' Leukemia & Lymphoma 37, (3-4) 309-317 , DOI

Pawson R, Davies J, McQuillan A, Rule S, Joske D, Spagnolo D & Erber W (1999) 'Immunophenotyping by flow cytometry of bone marrow but not peripheral blood is useful in staging of Non-Hodgkin's Lymphomas' BLOOD 94, (10) 252B-252B Author Site

Cunningham LM, Dunstan R, Joske DJ & Rule S (1999) 'Interleukin 10 promoter polymorphisms in Hodgkin's and non-Hodgkin's lymphoma' BLOOD 94, (10) 244B-244B Author Site

Rule S, McQuillan A, Pawson R, Davies J, Thomas W, Johnson S, Joske D & Erber W (1999) 'Non-cryopreserved stem cells for transplantation in patients with multiple myeloma' BLOOD 94, (10) 341B-341B Author Site

Rule S, Poirier V & Singer CRJ (1999) 'The investigation and management of patients with acute myeloblastic leukaemia in the South & West Region of the United Kingdom National Health Service' BLOOD 94, (10) 186A-186A Author Site

Pawson R, Davies J, Moy M, Spagnolo D, Joske D & Rule S (1999) 'Value of flow cytometry on lymph nodes and extranodal tissue samples in the diagnosis of patients with suspected Non-Hodgkin's Lymphoma' BLOOD 94, (10) 252B-252B Author Site

Tomlinson J, Tighe M, Johnson S, Stone R, Nicholson AG & Rule S (1999) 'Interstitial Pneumonitis Following Mitozantrone, Chlorambucil and Prednisolone (MCP) Chemotherapy' Clinical Oncology 11, (3) 184-186 , DOI

FREWIN R, TURNER D, TIGHE M, DAVIES S, RULE S & JOHNSON S (1999) 'Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders' British Journal of Haematology 104, (3) 612-613 , DOI

Turner DL, Johnson SA & Rule SA (1999) 'Successful treatment of candidal osteomyelitis with fluconazole following failure with liposomal amphotericin B' Journal of Infection 38, (1) 51-53 , DOI

Rohatiner AZS, Bassan R, Bjorkholm M, Rule S, Newland AC, Raimondi R, Carter M & Lister TA (1998) 'High-dose treatment (HDT) with peripheral blood progenitor cell (PBPC) support as consolidation of first remission in younger patients (Pts.) with acute myelogenous leukaemia (AML)' BLOOD 92, (10) 293A-293A Author Site

Rule S, Tighe M, Davies S & Johnson S (1998) 'Vinorelbine in the treatment of lymphoma' Hematological Oncology 16, (3) 101-105 , DOI

Bromidge TJ, Turner DL, Howe DJ, Johnson SA & Rule SAJ (1998) 'In vitro chemosensitivity of chronic lymphocytic leukaemia to purine analogues – correlation with clinical course' Leukemia 12, (8) 1230-1235 , DOI

Child JA, Morgan GJ, Smith GM, Johnson SAN, Rule S, Johnson PWM, Prentice AG & Tollerfield SM (1998) 'FluDAP as pre-autograft chemotherapy for recurrent/refractory non-Hodgkin's lymphoma' BRITISH JOURNAL OF HAEMATOLOGY 102, (1) 235-235 Author Site

Turner D, Tighe M, Johnson S, Davies SV, Phillips MJ, Frewin R & Rule S (1998) 'Mitozantrone, chlorambucil and prednisolone (MCP) in the treatment of elderly patients with high grade non-Hodgkin's lymphoma' BRITISH JOURNAL OF HAEMATOLOGY 102, (1) 242-242 Author Site

Frewin R, Turner D, Tighe M, Davies S, Rule S & Johnson S (1998) 'Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders' BRITISH JOURNAL OF HAEMATOLOGY 101, 40-40 Author Site

Rule S, Tighe M, Davies S & Johnson S (1998) 'Vinorelbine in the treatment of lymphoma' Hematological Oncology 16, (3) 101-105 , DOI

Bromidge TJ, Howe DJ, Johnson SA & Rule SA (1997) 'Heterogeneity of clonal lymphocytes with regard to bcl-2 protein concentration and cell size' Molecular Pathology 50, (6) 326-328 , DOI

Dokal I, Rule S, Chen F, Potter M & Goldman J (1997) 'Adult onset of acute myeloid leukaemia (M6) in patients with Shwachman‐Diamond syndrome' British Journal of Haematology 99, (1) 171-173 , DOI

Savage DG, Taylor P, Blackwell J, Chen F, Szydlo RM, Rule SAJ, Spencer A, Apperley JF & Goldman JM (1997) 'Paranasal sinusitis following allogeneic bone marrow transplant' Bone Marrow Transplantation 19, (1) 55-59 , DOI

Howe DJ, Bromidge TJ, Stack-Dunne M, Davies SV, Paxton A, Phillips MJ, Rule SJ & Johnson SA (1997) 'Trisomy 12 is a Rare Event in Cases of CLL with Typical Immunophenotype and Morphology' Hematology 2, (5) 373-378 , DOI

OBrien SG, Apperley JF, Szydlo R, Spencer A, Rule SA, Savage D, Blackwell J, Orchard K, Chase A & Hawkins TE (1996) 'High dose busulfan alone as cytoreduction before autografting for chronic myeloid leukemia - A feasibility study' BLOOD 88, (10) 3528-3528 Author Site

Rule SAJ, Savage DG, O'Brien SG, Orchard K, McDonald C, Davidson J, Matthey F, Reilly JT, Bardhan G & Miller E (1996) 'Intermediate‐dose busulphan before autografting for advanced‐phase chronic myeloid leukaemia' British Journal of Haematology 94, (4) 694-698 , DOI

Jager HR, Williams EJ, Savage DG, Rule SAJ, Hajnal JV, Sikora K, Goldman JM & Bydder GM (1996) 'Assessment of brain changes with registered MR before and after bone marrow transplantation for chronic myeloid leukemia' AMERICAN JOURNAL OF NEURORADIOLOGY 17, (7) 1275-1282 Author Site

OBrien SG, Spencer A, Rule S, Hawkins T, Savage D, Apperley JF, Chase AJ, McDonald C, Davidson RJ & Goldman JM (1996) 'Chronic phase CML autografting using PBPCs mobilised by intermediate-dose chemotherapy - An update of the Hammersmith experience' BRITISH JOURNAL OF HAEMATOLOGY 93, 278-278 Author Site

Howe D, Bromidge T, Johnson S & Rule S (1996) 'Dynamics of trisomy 12 clones before and during chemotherapy' BRITISH JOURNAL OF HAEMATOLOGY 93, 1078-1078 Author Site

Rohatiner AZS, Bassan R, Bjorkholm M, Rule S, Newland A, Apostolidis J & Raymondi R (1996) 'Myeloablative therapy with peripheral blood progenitor cell (PBPC) support as consolidation of first remission in younger patients with acute myelogenous Leukaemia (AML)' BRITISH JOURNAL OF HAEMATOLOGY 93, 849-849 Author Site

Rule S, Tighe M & Johnson S (1996) 'Vinorelbine (Navelbine) an active agent in the salvage of heavily pre-treated patients with Hodgkin's and non-Hodgkin's lymphoma' BRITISH JOURNAL OF HAEMATOLOGY 93, 1402-1402 Author Site

OBrien SG, Spencer A, Rule S, Hawkins T, Savage D, Apperley JF, Chase AJ, McDonald C, Davidson RJ & Goldman JM (1996) 'Chronic phase cml autografting using PBPCs mobilised by intermediate-dose chemotherapy an update of the Hammersmith experienc' BRITISH JOURNAL OF HAEMATOLOGY 93, 4-4 Author Site

Grubb H, Rule S & Johnson S (1996) 'Treatment of Waldenstrom's Macroglobulinaemia with fludarabine. Results in 7 patients with long term follow up' BRITISH JOURNAL OF HAEMATOLOGY 93, 277-277 Author Site

Sill H, Rule SAJ, Joske DJL, Chase A, Lin F, Goldman JM & Cross NCP (1996) 'Reconstitution with Philadelphia chromosome-negative recipient haematopoiesis early after allogeneic BMT for CML' BONE MARROW TRANSPLANTATION 17, (3) 453-455 Author Site

Spencer A, Szydlo RM, Brookes PA, Kaminski E, Rule S, van Rhee F, Ward KN, Hale G, Waldmann H & Hows JM (1995) 'Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient' Blood 86, (9) 3590-3597 , DOI

OBRIEN SG, GEWIRTZ AM, RULE SA, HAWKINS TE, RATAJCZAK MZ, SAVAGE D, LUGER SM & GOLDMAN JM (1995) 'AUTOGRAFTING FOR CML USING BONE-MARROW PURGED WITH MYB ANTISENSE OLIGONUCLEOTIDE' EXPERIMENTAL HEMATOLOGY 23, (8) 804-804 Author Site

Rule SAJ, O'Brien SG, Spencer A, Apperley J & Goldman JM (1995) 'Bone marrow transplantation' BMJ 310, (6983) 874-874 , DOI

Rule SA, O'Brien SG, Spencer A, Apperley J & Goldman JM (1995) 'Bone marrow transplantation. Review articles must accurately reflect current practice' BMJ (Clinical research ed.) 310, (6983)

Forbes GM, Rule SAJ, Herrmann RP, Davies JM & Collins BJ (1995) 'A prospective study of screening upper gastrointestinal (GI) endoscopy prior to and after bone marrow transplantation (BMT)' Australian and New Zealand Journal of Medicine 25, (1) 32-36 , DOI

Rule SAJ, Hooker M, Costello C, Luck W & Hoffbrand AV (1994) 'Serum vitamin B12 and transcobalamin levels in early HIV disease' American Journal of Hematology 47, (3) 167-171 , DOI

Erber WN, Asbahr H, Rule SA & Scott CS (1994) 'Unique immunophenotype of acute promyelocytic leukaemia as defined by CD9 and CD68 antibodies' British Journal of Haematology 88, (1) 101-104 , DOI

RULE S & DAVIES J (1994) 'Intermittent dosing of granulocyte colony stimulating factor (G-CSF) to facilitate palliative radiotherapy' Australian and New Zealand Journal of Medicine 24, (4) 402-402 , DOI

Rule SAJ, Erber WN, Lown JAG, Dale BJ, Herrmann RP & Davies JM (1994) 'Cross-matched platelets in bone marrow transplantation' Pathology 26, (3) 288-290 , DOI

HERRMANN RP, RULE SAJ, DAVIES JM & LEATHER HL (1993) 'SUBSTITUTION OF CARBOPLATIN FOR CISPLATIN IN THE DHAP (PARMA) REGIMEN IS EFFECTIVE SALVAGE THERAPY IN RELAPSED LYMPHOMA' EXPERIMENTAL HEMATOLOGY 21, (8) 1124-1124 Author Site

PERRETT K (1993) 'Epoetin in elective hip replacement' The Lancet 341, (8861) 1665-1665 , DOI

Rule SAJ, Waterhouse P, Costello C & Retsas S (1993) 'Paraneoplastic Eosinophilia in Malignant Melanoma' Journal of the Royal Society of Medicine 86, (5) 295-295 , DOI

Rule S, Brooksby P & Sanderson J (1993) 'Use of thrombolysis for acute myocardial infarction by general practitioners' Postgraduate Medical Journal 69, (809) 190-193 , DOI

Rule S & Erber W (1993) 'Epoetin in elective hip replacement' Lancet 341, (8861)

Costello C, Rule S, Shanson D & Mir N (1992) 'Bone-marrow diagnosis of opportunistic infections in HIV disease' AIDS 6, (12) 1559-1560 , DOI

Rule S, Reed C & Costello C (1991) 'FATAL HAEMOPHAGOCYTIC SYNDROMES IN HIV-ANTIBODY POSITIVE PATIENT' British Journal of Haematology 79, (1) 127-127 , DOI

Whelan JS, Davis CL, Rule S, Ranson M, Smith OP, Mehta AB, Catovsky D, Rohatiner AZS & Lister TA (1991) 'Fludarabine phosphate for the treatment of low grade lymphoid malignancy' British Journal of Cancer 64, (1) 120-123 , DOI Open access

McCarthy D, Samson D, Mir N, Rule S, Nadir F, Taylor J & Costello C (1991) 'Response to trans-retinoic acid in an AMLM3 patient resistant to cis-retinoic acid' Leukemia Research 15, (8) 765-765 , DOI

Letters

Forbes A, Farrell K, McKay P, Bolam S & Rule S (2013) 'High dose cytarabine with rituximab is an effective first-line therapy for mantle cell lymphoma and produces ample stem cell harvest yields after multiple chemotherapy cycles' Leuk Lymphoma 54, (10) 2303-2305 Author Site , DOI

Shah N & Rule S (2013) 'Rituximab administration in a community hospital environment' Leuk Lymphoma 54, (7) 1532-1533 Author Site , DOI

Chapters

Silkenstedt E, Dreyling M & Rule S (2021) 'Mantle Cell Lymphoma' Hematologic Malignancies Springer International Publishing 163-178 , DOI

Conference Papers

Visco C, Di Rocco A, Evangelista A, Quaglia FM, Tisi MC, Morello L, Zilioli VR, Rusconi C, Hohaus S & Sciarra R (2020) 'Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study' Springer Science and Business Media LLC 787-795 , DOI

Fraser GAM, Chanan-Khan A, Demirkan F, Santucci Silva R, Grosicki S, Janssens A, Mayer J, Bartlett NL, Dilhuydy M-S & Loscertales J (2020) 'Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma' Taylor & Francis 3188-3197 , DOI Open access

Rusconi C, Tucker D, Bernard S, Muzi C, Crucitti L, Stefani P, Cox M, Gini G, Re A & Sciarra R (2019) 'IBRUTINIB COMPARED TO STANDARD CHEMOTHERAPY FOR CENTRAL NERVOUS SYSTEM RECURRENCE OF MANTLE CELL LYMPHOMA' Wiley 244-245 , DOI

Rule S (2019) 'The modern approach to mantle cell lymphoma' Wiley 66-69 , DOI

Peggs K, Cook G, Russell N, Hunter A, Robinson S, Morley N, Sureda A, Smith P, Patrick P & Braganca N (2016) 'Reduced Intensity Conditioning transplantation (RIC) as part of first line therapy for Mantle cell lymphoma: results from the Phase II Mini Allo trial (CRUK: C7627/A9080)' S69-S69

Cramer P, Chanan-Khan A, Fraser G, Demirkan F, Santucci Silva R, Pylypenko H, Grosicki S, Janssens A, Goy A & Mayer J (2015) 'Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)' American Society of Hematology 2938-2938 , DOI

Hillmen P, Fraser G, Jones J, Rule S, O'Brien S, Dilhuydy MS, Jaeger U, Grosicki S, Cymbalista F & Sun S (2015) 'Comparing Single-Agent Ibrutinib, Bendamustine Plus Rituximab (BR) and Ibrutinib Plus BR in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): An Indirect Comparison of the RESONATE and HELIOS Trials' American Society of Hematology 2944-2944 , DOI

Rule S, Jurczak W, Jerkeman M, Santucci R, Rusconi C, Trneny M, Offner F, Caballero D, Joao C & Witzens-Harig M (2015) 'Ibrutinib Vs Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL)' American Society of Hematology 469-469 , DOI

Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Santucci Silva R, Pylypenko H, Grosicki S, Janssens A, Pristupa A & Goy A (2015) 'Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab' American Society of Hematology 2936-2936 , DOI

Hess G, Rule S, Jurczak W, Jerkeman M, Santucci R, Rusconi C, Caballero D, Joao CM, Witzens-Harig M & Bence-Bruckler I (2015) 'Lymphoma Symptoms: Data from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL) Treated with Ibrutinib Vs. Temsirolimus' American Society of Hematology 1542-1542 , DOI

Chanan-Khan AAA, Cramer P, Demirkan F, Fraser G, Silva RS, Pylypenko H, Grosicki S, Janssens A, Pristupa A & Mayer J (2015) 'Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study' American Society of Clinical Oncology (ASCO) LBA7005-LBA7005 , DOI

Cramer P, Chanan-Khan A, Demirkan F, Fraser G, Santucci Silva R, Pylypenko H, Grosicki S, Janssens A, Pristupa A & Mayer J (2015) 'IBRUTINIB COMBINED WITH BENDAMUSTINE/RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): FIRST RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY' 55-56

Trneny M, Lamy T, Walewski J, Belada D, Mayer J, Radford J, Jurczak W, Morschhauser F, Alexeeva J & Rule S (2015) 'IMPACT OF PRIOR TREATMENT ON PFS FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS RANDOMIZED TO LENALIDOMIDE VS INVESTIGATOR'S CHOICE: A SUBGROUP ANALYSIS OF THE PHASE II MCL-002 (SPRINT) STUDY' 4-4

Rule S, Arcaini L, Walewski J, Skotnicki A, Belada D, Mayer J, Alexeeva J, Afanasyev B, Kuzmin A & Jurczak W (2015) 'QUALITY OF LIFE IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS TREATED WITH LENALIDOMIDE VS INVESTIGATOR'S CHOICE: MCL-002 (SPRINT) TRIAL' 147-147

Trneny M, Lamy T, Walewski JA, Belada D, Mayer J, Radford JA, Jurczak W, Morschhauser F, Alexeeva J & Rule S (2015) 'Subgroup analysis of the phase II randomized MCL-002 (SPRINT) study of lenalidomide vs investigator's choice in relapsed/refractory mantle cell lymphoma'

Tucker DL, Hasan M, Poplar S, Rockett M & Rule S (2015) 'Does trans-cutaneous electrical nerve stimulation (TENS) alleviate the pain experienced during bone marrow sampling in addition to standard techniques? A randomised, double-blinded, controlled trial' 34-35

Dyer MJS, Grigg A, Diaz MG, Dreyling M, Rule S, Lei G, Wassner-Fritsch E, Knapp A & Marlton P (2015) 'Obinutuzumab (GA101) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or bendamustine for the first-line treatment of follicular non-Hodgkin lymphoma: final results from the maintenance phase of the phase Ib GAUDI study' 53-53

Shah NK, Richardson S & Rule S (2015) 'Significant gender differences in the number and distribution of T cells in patients with mantle cell lymphoma' 54-55

Rule S, Goy A, Martin P, Ramchandren R, Alexeeva J, Popat R, Avivi I, Advani R, Le Gouill S & Horowitz N (2015) 'Single-agent ibrutinib for the treatment of mantle cell lymphoma (MCL): evaluating the link between durable response and quality of life (QoL) in the SPARK study' 59-59

Wang M, Goy A, Martin P, Ramchandren R, Alexeeva J, Popat R, Avivi I, Advani R, Le Gouill S & Horowitz N (2014) 'Efficacy and Safety of Single-Agent Ibrutinib in Patients with Mantle Cell Lymphoma Who Progressed after Bortezomib Therapy' American Society of Hematology 4471-4471 , DOI

Dyer MJS, Grigg AP, González Díaz M, Dreyling M, Rule S, Lei G, Wassner-Fritsch E, Fingerle-Rowson G & Marlton PV (2014) 'Obinutuzumab (GA101) in Combination with CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) or Bendamustine for the First-Line Treatment of Follicular Non-Hodgkin Lymphoma: Final Results from the Maintenance Phase of the Phase Ib GAUDI Study' American Society of Hematology 1743-1743 , DOI

Fegan C, Bagshawe J, Salles G, Karlin L, Rule S, Shah N, Morschhauser F, Terriou L, Dyer MJS & Walter H (2014) 'The Bruton’s Tyrosine Kinase (BTK) Inhibitor ONO-4059: Promising Single Agent Activity and Well Tolerated in Patients with High Risk Chronic Lymphocytic Leukaemia (CLL)' American Society of Hematology 3328-3328 , DOI

Fegan C, Bagshawe J, Salles G, Karlin L, Rule S, Shah N, Morschhauser F, Terriou L, Dyer M & Hutchinson C (2014) 'A PHASE I STUDY OF THE ORAL BTK INHIBITOR ONO-4059 IN PATIENTS WITH RELAPSED/REFRACTORY AND HIGH RISK CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)' 250-250

Rule S, Wang ML, Martin P, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera J, Williams M & Barrientos JC (2014) 'PHASE 2 STUDY OF IBRUTINIB IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: UPDATED SAFETY ANALYSIS ON PREVALENCE OF INFECTION, DIARRHEA, AND BLEEDING OVER TIME' 150-150

Morschhauser F, Terriou L, Dyer M, Hutchinson C, Rule S, Shah N, Salles G, Karlin L, Fegan C & Bagshawe J (2014) 'THE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR ONO-4059: PROMISING SINGLE AGENT ACTIVITY IN PATIENTS WITH RELAPSED AND REFRACTORY NHL' 150-150

Dyer M, Hutchinson C, Rule S, Shah N, Salles GA, Karlin L, Morschhauser F, Terriou L, Fegan C & Davison A (2014) 'The Bruton’s tyrosine kinase (BTK) inhibitor ONO-4059: Single-agent activity in patients with relapsed and refractory non-GCB-DLBCL' American Society of Clinical Oncology (ASCO) 8553-8553 , DOI

Shah NK, Rule S, Salles G, Karlin L, Morschhauser F, Terriou L, Dyer M, Hutchinson C, Fegan C & Davison A (2014) 'A phase I study of the oral Btk inhibitor ONO-4059 in patients with relapsed/refractory B-cell lymphoma' 57-58

Rule S, Briones J, Carella AM, Casasnovas O, Barreto WG, Pocock C, Osborne S, Smith R & Zaja F (2014) 'Extending subcutaneous rituximab maintenance therapy from 2 years until progression versus observation in patients with indolent non-Hodgkin's lymphoma: interim safety data from the MABCUTE study' 67-68

Furtado MV, Shah NK & Rule SAJ (2014) 'Fixed dose rituximab for diffuse large B cell lymphoma treated with R-CHOP - a retrospective audit' 56-56

Furtado MV, Munneke B, Wang M, Beaupre D, McGreivy J & Rule S (2014) 'Ibrutinib associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma' 64-64

Hillmen P, Pettitt A, Schuh A, Milligan D, Bowles K, Bareford D, Riaz JM, Follows G, Rule S & Wallis J (2014) 'Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted)' 19-20

Tucker DL, Rogers B, Court N & Rule SA (2014) 'Primary prophylaxis with G-CSF is unnecessary to maintain dose intensity and prevent unplanned hospitalisations and treatment delays. A two year retrospective cohort study of R-CHOP21 for diffuse large B-cell lymphoma in a regional tertiary referral unit' 52-52

Shah NK, Furtado M, Crosbie N & Rule S (2014) 'Single centre outcome of mantle cell lymphoma over the past decade' 57-57

Townsend W, Kirkwood A, Patel A, Smith P & Rule S (2014) 'Systemic treatment of relapsed mantle cell lymphoma after initial treatment with fludarabine and cyclophosphamide with or without rituximab: long-term follow-up of a large randomised trial' 66-66

Rule S, Wang M, Martin P, Auer R, Kahl B, Jurczak W, Advani R, Romaguera J, Williams M & Barrientos J (2013) 'UPDATED INTERIM RESULTS OF AN INTERNATIONAL, MULTICENTER, PHASE 2 STUDY OF IBRUTINIB (PCI-32765) IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA' 489-489

Wang M, Rule SA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JEE & McGreivy J (2012) 'Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up' American Society of Hematology 904-904 , DOI

Dyer MJS, Grigg A, Gonza´lez M, Dreyling M, Rule SA, Lei G, Wassner-Fritsch E, Wenger MK & Marlton P (2012) 'Obinutuzumab (GA101) in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) or Bendamustine in Patients with Previously Untreated Follicular Lymphoma (FL): Results of the Phase Ib GAUDI Study (BO21000)' American Society of Hematology 3686-3686 , DOI

Furtado MV, Shah NK, Levoguer A, Harding S & Rule S (2012) 'Abnormal serum free light chain ratio predicts inferior overall survival in mantle cell lymphoma' 46-47

Eve HE, Carey S, Richardson SJ, Heise CC, Mamidipudi V, Shi T, Radford JA, Auer RL, Bullard SH & Rule SAJ (2012) 'Efficacy and safety of conventional-dose lenalidomide followed by low-dose maintenance lenalidomide for relapsed/refractory mantle cell lymphoma (MCL): updated results from a UK phase II study' 14-14

Forbes A, Rule S, Farrell K, McKay P, Bolam S & Kruger A (2012) 'First line treatment of mantle cell lymphoma with high dose cytarabine and rituximab' 51-51

Furtado MV & Rule S (2012) 'First UK experience of BTK inhibitor PCI-32765-dramatic responses in relapsed/refractory mantle cell lymphoma' 47-48

Furtado MV, Riordan R, Dyer MJS & Rule S (2012) 'Interim analysis results of a phase II trial of single agent ofatumumab in the treatment of relapsed/refractory mantle cell lymphoma' 47-47

Rule S, Smith P, Johnson P, Bolam S, Follows G, Gambell J, Hillmen P, Jack A, Johnson S & Kirkwood A (2012) 'The addition of rituximab to fludarabine and cyclophosphamide (FC) improves overall survival in newly diagnosed mantle cell lymphoma (MCL): results of the randomised UK National Cancer Research Institute (NCRI) trial' 12-12

Rule S, Smith P, Johnson PW, Bolam S, Follows GA, Gambell J, Hillmen P, Jack A, Johnson SAN & Kirkwood A (2011) 'The Addition of Rituximab to Fludarabine and Cyclophosphamide (FC) Improves Overall Survival in Newly Diagnosed Mantle Cell Lymphoma (MCL): Results of the Randomised UK National Cancer Research Institute (NCRI) Trial' 202-203 , DOI

Eve HE, Bullard SH & Rule SA (2011) 'EFFICACY AND SAFETY OF CONVENTIONAL-DOSE LENALIDOMIDE FOLLOWED BY LOW-DOSE MAINTENANCE LENALIDOMIDE FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (MCL): RESULTS FROM A UK PHASE II STUDY' 222-222

Furtado M, Eve H & Rule S (2011) 'LENALIDOMIDE TREATMENT - SAFE TO ADMINISTER TO CYTOPENIC PATIENTS' 222-222

Eve H, Carey S & Rule S (2011) 'POSITIVE CORRELATION BETWEEN CIRCULATING NK CELLS AND DISEASE RESPONSE IN MANTLE CELL LYMPHOMA (MCL) TREATED WITH LENALIDOMIDE: FIRST IN VIVO DATA SUPPORTING NK-MEDIATED CYTOTOXICITY AS A MECHANISM OF ACTION' 198-198

Furtado M, Shah N, Eve H, Levoguer A, Harding S & Rule S (2011) 'SERUM FREE LIGHT CHAIN RATIO - A POTENTIAL BIOMARKER FOR MANTLE CELL LYMPHOMA' 220-220

Giles JA, Moony J, Pearce A, Hunter HM, Smith S, Rule S, Pottinger B & Hamon MD (2011) 'Automated peripheral blood haematopoietic progenitor cell anaylsis on the Sysmex XE2100 and prediction of peripheral blood stem cell harvest timing' S358-S358

Hellmann A, Rule SA, Walewski J, Shpilberg O, Feng HB, van de Velde H, Patel H, Skee DM, Girgis S & Louw V (2010) 'Effect of the Cytochrome P450 3A4 Inducers, Rifampicin and Dexamethasone, on the Pharmacokinetic, Pharmacodynamic and Safety Profile of Bortezomib In Patients with Multiple Myeloma (MM) and Non Hodgkin's Lymphoma (NHL)' 52nd Annual Meeting of the American-Society-of-Hematology (ASH) Orlando, FL 2-/-1/20102-/-1/2010AMER SOC HEMATOLOGY 1624-1624

Eve E, Richardson J & Rule S (2010) 'DOWNREGULATION OF CD19, CD20 AND CD22 SURFACE EXPRESSION ON MANTLE CELL LYMPHOMA BY LENALIDOMIDE' 608-609

Ngu LSP, Hyatt N, Eccleston T, Copplestone JA, Eve H, Rule SA & Thomas DW (2010) 'Basal tissue factor levels are higher in patients with mantle cell lymphoma prior to lenalidamide therapy compared to controls' 39-39

Eve HE, Bullard SH & Rule SAJ (2010) 'Efficacy and safety of single-agent lenalidomide for relapsed/refractory mantle cell lymphoma (MCL): Preliminary results from a UK-based open-label phase II trial' 42-43

Miles OA, Eve HE, Riordan RD & Rule SA (2010) 'Orbital relapse of mantle cell lymphoma and response to novel treatment regimens' 44-44

Ngu LSP, Hyatt N, Caveen C, Copplestone JA, Eve H, Rule SA & Thomas DW (2010) 'Use of the thrombin generation assay (calibrated automated thrombogram) in patients with multiple myeloma and mantle cell lymphoma on thalidomide or lenalidamide therapy' 38-39

Eve H, Determann O, Klapper W, Smith P, Qian W & Rule S (2009) 'Ki-67 does not predict survival in newly-diagnosed mantle cell lymphoma treated with fludarabine and cyclophosphamide (FC) with or without rituximab (R)' 87-87

Eve H, Bullard S & Rule S (2009) 'Preliminary toxicity results from a phase II trial of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy with or without Bortezomib for mantle cell lymphoma in first relapse' 12-12

Agathocleous A, Rule S, Johnson P, Radford JA, Lafon N, Hunter H, Kerr JP, Neeson SM, Matthews J & Strauss S (2007) 'Preliminary results of a phase I/II study of weekly or twice weekly bortezomib in combination with rituximab, in patients with follicular lymphoma, mantle cell lymphoma and Waldenstrom's macroglobulinaemia' 754A-754A

Pace E, Dennison S, Morris J, Rule S, Pritchard C, Barton A & Loving J (2007) 'A study to compare patient satisfaction with location of chemotherapy: community hospital versus cancer centre' 461-461 , DOI

Pace E, Dennison S, Morris J, Rule S, Pritchard C, Barton A & Loving J (2007) 'A randomised crossover study of a nurse-led chemotherapy outreach project' 462-462 , DOI

Oakervee H, Popat R, Hamblin M, Rule S, Rahemtulla A & Cavenagh J (2007) 'Longterm follow up of T-VAD for untreated multiple myeloma' 177-178

Eve H, Smith P, Qian W, Stevens L & Rule S (2007) 'Toxicity of fludarabine and cyclophosphamide (FC) +/- rituximab (R) as initial therapy for patients with previously-untreated mantle cell lymphoma: results of a randomised phase II study' 19-19

Richardson SJ, Copplestone JA & Rule SAJ (2007) 'CC-5013 (revlimid, lenalinomide) induces in vitro PBMC-toxicity against mantle cell lymphoma and this is enhanced by rituximab' 19-19

Eve HE & Rule SAJ (2007) 'Impairment of peripheral blood stem cell mobilisation in patients with mantle cell lymphoma following primary treatment with fludarabine-based chemotherapy' 17-18

El-Najjar I, Rule SAJ & Nokes TJC (2006) 'A fixed, low dose of anti-CD20 antibody (Rituximab) is an effective treatment for patients with chronic immune thrombocytopenia' 79-80

Rule S, Turner D, Smith S, Ewings P & Johnson S (2005) 'A phase II study of S/C cladribine and oral cyclophosphamide in relapsed/refractory lymphoproliferative disorders' 204-205

Rule S, Burton C, Waleski J, Jack A & Seymour J (2005) 'A randomised phase II study of fludarabine/cyclophosphamide +/-rituximab in patients with untreated mantle cell lymphoma' 95-95

Hunter H & Rule S (2005) 'Reduced course rasburicase remains effective in the prophylaxis of tumour lysis syndrome in at risk patients with high grade non Hodgkins lymphoma' 211-211

Hunter HM & Rule SAJ (2005) 'Rasburicase is effective in the prophylaxis of tumour lysis syndrome when used over a short duration in patients with haematological malignancy' 42-42

Harries LW, Wickham CL, Rule SA, Joyner MV & Ellard S (2004) 'Improved quantitation of haematopoietic chimaerism by real-time polymerase chain reaction' 39-39

Duckworth AW, Farrugia J, Copplestone A, Prentice AG & Rule SAJ (2002) 'Cyclin D1 mRNA transcript quantification in peripheral blood of mantle cell lymphoma patients - A robust diagnostic test' 280B-280B

Presentations and posters

Phillips E, Burton C, Kirkwood A, Barrans S, Lawrie A, Rule S, Patmore R, Pettengell R, Ardeshna K & Montoto S Phillips E, Burton C, Kirkwood A, Barrans S, Lawrie A, Rule S, Patmore R, Pettengell R, Ardeshna K & Montoto S 'High discrepancy rates in the diagnosis of Burkitt lymphoma: pathology and updated survival results from the UK NCRI/LLR R-CODOX-M trial' Author Site

Mihailescu L, Crosbie N & Rule S Mihailescu L, Crosbie N & Rule S 'The Plymouth experience of bleeding complications associated with concomitant treatment with BTK inhibitors and anticoagulants or antiplatelet drugs' Author Site

Morschhauser F, Awada A, Machiels J-P, Salles GA, Rottey S, Rule S, Cunningham D, Peyrade F, Fruchart C & Arkenau H-T Morschhauser F, Awada A, Machiels J-P, Salles GA, Rottey S, Rule S, Cunningham D, Peyrade F, Fruchart C & Arkenau H-T 'PHARMACOKINETIC AND PHARMACODYNAMIC RELATIONSHIPS OF COPANLISIB IN PATIENTS WITH NON-HODGKIN LYMPHOMA AND ADVANCED SOLID TUMORS' Author Site

Stankovic T, Yap C, Oldreive C, Slade D, Bishop R, Griffiths M, Dyer M, Fegan C, Oscier D & Pettitt A Stankovic T, Yap C, Oldreive C, Slade D, Bishop R, Griffiths M, Dyer M, Fegan C, Oscier D & Pettitt A 'A phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma' Author Site

Cramer P, Fraser G, Chanan-Khan A, Demirkan F, Santucci Silva R, Pylypenko H, Grosicki S, Janssens A, Pristupa A & Mayer J Cramer P, Fraser G, Chanan-Khan A, Demirkan F, Santucci Silva R, Pylypenko H, Grosicki S, Janssens A, Pristupa A & Mayer J 'Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study' Author Site

Thompson HP, Tucker DL, Rule SA & Hutchinson CV Thompson HP, Tucker DL, Rule SA & Hutchinson CV 'IRF4 EXPRESSION IS ASSOCIATED WITH RESPONSE OF MANTLE CELL LYMPHOMA TO BRUTON'S TYROSINE KINASE INHIBITORS' Author Site

Cramer P, Fraser G, Chanan-Khan A, Demirkan F, Silva SR, Pylypenko H, Grosicki S, Janssens A, Pristupa A & Mayer J Cramer P, Fraser G, Chanan-Khan A, Demirkan F, Silva SR, Pylypenko H, Grosicki S, Janssens A, Pristupa A & Mayer J 'Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study' Author Site

Fraser G, Cramer P, Demirkan F, Santucci Silva R, Grosicki S, Janssens A, Mayer J, Dilhuydy MS, Pylypenko H & Loscertales J Fraser G, Cramer P, Demirkan F, Santucci Silva R, Grosicki S, Janssens A, Mayer J, Dilhuydy MS, Pylypenko H & Loscertales J 'IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY' Author Site

Arcaini L, Rule S, Lamy T, Walewski J, Belada D, Mayer J, Radford J, Jurczak W, Morschhauser F & Alexeeva J Arcaini L, Rule S, Lamy T, Walewski J, Belada D, Mayer J, Radford J, Jurczak W, Morschhauser F & Alexeeva J 'MCL-002: UPDATED EFFICACY AND SAFETY RESULTS FOR LENALIDOMIDE VSINVESTIGATOR'S CHOICE MONOTHERAPY IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA' Author Site

Rule S, Dreyling M, Hess G, Auer R, Kahl B, Cavazos N, Liu B, Clow F, Goldberg J & Beaupre D Rule S, Dreyling M, Hess G, Auer R, Kahl B, Cavazos N, Liu B, Clow F, Goldberg J & Beaupre D 'OVERALL SURVIVAL OUTCOMES IN PATIENTS WITH MANTLE-CELL LYMPHOMA (MCL) TREATED WITH IBRUTINIB IN A POOLED ANALYSIS OF 370 PATIENTS FROM 3 INTERNATIONAL OPEN-LABEL STUDIES' Author Site

Rule S, Diels J, Healy N, Iraqi W, Aschan J & Wildgust M Rule S, Diels J, Healy N, Iraqi W, Aschan J & Wildgust M 'REAL-WORLD EXPERIENCE OF IBRUTINIB IN > 700 PATIENTS WITH MANTLE-CELL LYMPHOMA: DATA FROM A GLOBAL NAMED PATIENT PROGRAM' Author Site

Rule S, Peggs K, Russell N, Cook G, Hunter A, Morley N, Sureda A, Smith P, Patrick P & Braganca N Rule S, Peggs K, Russell N, Cook G, Hunter A, Morley N, Sureda A, Smith P, Patrick P & Braganca N 'REDUCED INTENSITY CONDITIONING TRANSPLANTATION (RIC) AS PART OF FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: RESULTS FROM THE PHASE II MINI ALLO TRIAL (CRUK: C7627/A9080)' Author Site

Burrows S, Tucker D, Naylor G, Wardrope K, Bolam S, McKay P, Forbes A & Rule S Burrows S, Tucker D, Naylor G, Wardrope K, Bolam S, McKay P, Forbes A & Rule S 'RITUXIMAB AND HIGH DOSE CYTARABINE WITH AUTOLOGOUS TRANSPLANTATION FOR MANTLE CELL LYMPHOMA' Author Site

Lenz G, Balasubramanian S, Goldberg J, Rizo A, Schaffer M, Phelps C, Rule S & Dreyling M Lenz G, Balasubramanian S, Goldberg J, Rizo A, Schaffer M, Phelps C, Rule S & Dreyling M 'SEQUENCE VARIANTS IN PATIENTS WITH PRIMARY AND ACQUIRED RESISTANCE TO IBRUTINIB IN THE PHASE 3 MCL3001 (RAY) TRIAL' Author Site

McMillan A, Rule S, Patmore R, Pettengell R, Burton C, Kirkwood A, Ardeshna K, Gambell J, Jack A & Lawrie A McMillan A, Rule S, Patmore R, Pettengell R, Burton C, Kirkwood A, Ardeshna K, Gambell J, Jack A & Lawrie A 'Front line therapy with R-CODOX-M & R-IVAC in poor risk diffuse large B cell lymphoma (IPI 3-5) yields a good outcome without transplantation: A phase 2 UK NCRI/Bloodwise Trial' Author Site

Rule S, Diels J, Healy N, Iraqi W, Aschan J & Wildgust M Rule S, Diels J, Healy N, Iraqi W, Aschan J & Wildgust M 'Global mantle cell lymphoma (MCL) named patient program (NPP) experience in > 790 patients treated with ibrutinib' Author Site

Tucker DL, Vandenberghe E, Morley N, Bowles K & Rule S Tucker DL, Vandenberghe E, Morley N, Bowles K & Rule S 'Real world experience of ibrutinib in mantle cell lymphoma - prospective multi-centre data from 61 patients treated for MCL with ibrutinib (single agent) via the expanded access programme in Great Britain and Ireland' Author Site

Tucker DL, Peggs KS, Cook G, Russell N, Hunter A, Robinson S, Morley NJ, Sureda A, Smith P & Patrick P Tucker DL, Peggs KS, Cook G, Russell N, Hunter A, Robinson S, Morley NJ, Sureda A, Smith P & Patrick P 'Reduced intensity conditioned allogeneic stem cell transplantation (RIC-Allo) as front-line therapy for mantle cell lymphoma (MCL): Results from the UK Phase II Mini Allo Study (CRUK: C7627/A9080)' Author Site

McMillan A, Rule S, Patmore R, Pettengell R, Burton C, Kirkwood A, Ardeshna K, Gambell J, Jack A & Lawrie A McMillan A, Rule S, Patmore R, Pettengell R, Burton C, Kirkwood A, Ardeshna K, Gambell J, Jack A & Lawrie A 'The addition of rituximab to CODOX-M & IVAC in first line therapy of poor risk Burkitt lymphoma (IPI 3-5) yields an excellent outcome: A phase 2 UK NCRI/Bloodwise Trial (LLR 04058)' Author Site

Rule S, Kater AP, Brümmendorf TH, Fegan C, Kaiser M, Radford JA, Stilgenbauer S, Kayser S, Dyer MJS & Brossart P Rule S, Kater AP, Brümmendorf TH, Fegan C, Kaiser M, Radford JA, Stilgenbauer S, Kayser S, Dyer MJS & Brossart P 'A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies' , DOI

Hutchings M, Lugtenburg P, Mous R, Clausen MR, Chamuleau M, Linton K, Rule S, Lopez J, Oliveri RS & DeMarco D Hutchings M, Lugtenburg P, Mous R, Clausen MR, Chamuleau M, Linton K, Rule S, Lopez J, Oliveri RS & DeMarco D 'ABCL-346: Subcutaneous (SC) Epcoritamab (GEN3013; DuoBody-CD3×CD20) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL): Dose-Escalation Data from a Phase I/II Trial' , DOI

Owen R, McCarthy H, Rule S, D'Sa S, Thomas S, Forconi F, Anderson T, Kersten MJ, Zinzani PL & Iyengar S Owen R, McCarthy H, Rule S, D'Sa S, Thomas S, Forconi F, Anderson T, Kersten MJ, Zinzani PL & Iyengar S 'Acalabrutinib in Patients (pts) with Waldenstrom Macroglobulinemia (WM)' Author Site , DOI

McCulloch R, Smith A, Wainman B, Ingram W, Lewis A, Hawkins M, Crosbie N, Pettitt A & Rule S McCulloch R, Smith A, Wainman B, Ingram W, Lewis A, Hawkins M, Crosbie N, Pettitt A & Rule S '40% of Females with Mantle Cell Lymphoma Are Managed with Initial Observation: Results from the MCL Biobank Observational Study' , DOI

Owen R, McCarthy H, Rule S, D'Sa S, Thomas SK, Forconi F, Anderson TC, Kersten MJ, Zinzani PL & Iyengar S Owen R, McCarthy H, Rule S, D'Sa S, Thomas SK, Forconi F, Anderson TC, Kersten MJ, Zinzani PL & Iyengar S 'Acalabrutinib in patients (pts) with Waldenström macroglobulinemia (WM)' , DOI

Dyer MJS, De Vos S, Ruan J, Flowers C, Maddocks KJ, Rule S, Hamdy AM, Izumi R, Slatter JG & Cheung J Dyer MJS, De Vos S, Ruan J, Flowers C, Maddocks KJ, Rule S, Hamdy AM, Izumi R, Slatter JG & Cheung J 'Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)' , DOI

Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn JK, Lamy T & Morschhauser F Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn JK, Lamy T & Morschhauser F 'ACALABRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: FINAL RESULTS FROM A PHASE 2 STUDY' , DOI

Wang M, Rule S, Zinzani PL, Goy AH, Casasnovas R-O, Smith SD, Damaj GL, Doorduijn JK, Lamy T & Morschhauser F Wang M, Rule S, Zinzani PL, Goy AH, Casasnovas R-O, Smith SD, Damaj GL, Doorduijn JK, Lamy T & Morschhauser F 'Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results from a Phase 2 Study' , DOI

Casulo C, Santoro A, Ando K, Le Gouill S, Ruan J, Radford J, Arcaini L, Pinto A, Bouabdallah R & Izutsu K Casulo C, Santoro A, Ando K, Le Gouill S, Ruan J, Radford J, Arcaini L, Pinto A, Bouabdallah R & Izutsu K 'Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial' , DOI

Fowler NH, Flinn I, Rule S, Chen RW, Kwei L, Beaupre DM, Chu AD & Gordon LI Fowler NH, Flinn I, Rule S, Chen RW, Kwei L, Beaupre DM, Chu AD & Gordon LI 'A multicenter, randomized, double-blind, placebo-controlled phase III study of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, in combination with rituximab versus placebo in combination with rituximab in patients with treatment-naive follicular lymphoma (PERSPECTIVE)' , DOI

Hutchings M, Lugtenburg P, Mous R, Clausen MR, Chamuleau M, Linton K, Rule S, Lopez JS, Oliveri RS & DeMarco D Hutchings M, Lugtenburg P, Mous R, Clausen MR, Chamuleau M, Linton K, Rule S, Lopez JS, Oliveri RS & DeMarco D 'Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial' , DOI

Flinn I, Gordon L, Rule S, Chen R, Kwei L, Chu AD & Fowler N Flinn I, Gordon L, Rule S, Chen R, Kwei L, Chu AD & Fowler N 'IBCL-094: Combination of Ibrutinib with Rituximab Versus Placebo with Rituximab for First-Line Treatment of Follicular Lymphoma: PERSPECTIVE, a Randomized Phase 3 Study' , DOI

Fraser G, Cramer P, Demirkan F, Santucci Silva R, Pylypenko H, Grosicki S, Janssens A, Pristupa A, Mayer J & Dilhuydy M-S Fraser G, Cramer P, Demirkan F, Santucci Silva R, Pylypenko H, Grosicki S, Janssens A, Pristupa A, Mayer J & Dilhuydy M-S 'Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study' , DOI

Korfi K, Araf S, Bewicke-Copley F, Kumar E, Cummin T, Ashton-Key M, Barrans S, Van Hoppe S, Burton C & Elshiekh M Korfi K, Araf S, Bewicke-Copley F, Kumar E, Cummin T, Ashton-Key M, Barrans S, Van Hoppe S, Burton C & Elshiekh M 'LONGITUDINAL ANALYSES OF DIAGNOSTIC-RELAPSE BIOPSIES OF DIFFUSE LARGE B CELL LYMPHOMA SUGGEST THAT RELAPSE IS MEDIATED BY DISTINCT MECHANISMS IN ABC AND GCB LYMPHOMA' , DOI

Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn JK, Lamy T & Morschhauser F Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn JK, Lamy T & Morschhauser F 'Long-Term Follow-up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma' , DOI

Rule S, Dreyling MH, Goy A, Hess G, Auer R, Kahl BS, Hernandez-Rivas JA, Qi K, Deshpande S & Parisi L Rule S, Dreyling MH, Goy A, Hess G, Auer R, Kahl BS, Hernandez-Rivas JA, Qi K, Deshpande S & Parisi L 'Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up' , DOI

McCulloch R, Berrow M, Wainman B, Crosbie N & Rule S McCulloch R, Berrow M, Wainman B, Crosbie N & Rule S 'MIPI and Ki67 do not predict suitability for watch-and-wait in mantle-cell lymphoma: update from the MCL Biobank study' Author Site

Critchlow S, Lee D, Latour A, Wildgust M, Goldberg J, Rule S & Wang M Critchlow S, Lee D, Latour A, Wildgust M, Goldberg J, Rule S & Wang M 'Modelling the Effectiveness of Ibrutinib Versus Rituximab-Based Chemotherapy Regimens in Relapsed/Refractory Mantle Cell Lymphoma' , DOI

Jurczak W, Rule S, Townsend W, Tucker D, Sarholz B, Scheele J, Gribben JG & Zinzani PL Jurczak W, Rule S, Townsend W, Tucker D, Sarholz B, Scheele J, Gribben JG & Zinzani PL 'A Phase I/II, First in Human Trial of the Bruton's Tyrosine Kinase Inhibitor M7583 in Patients with B-Cell Malignancies' , DOI

Zaidi A, Mindos T, Hutchinson C, Rule S & McCallum L Zaidi A, Mindos T, Hutchinson C, Rule S & McCallum L 'Dysregulation of CCN1 expression in conjunction with increased expression of p21(CIP1) and p27(KIP1) implicated in mantle cell lymphoma progression' Author Site

Fowler N, Flinn IW, Rule S, Chen R, Kwei L, Chu AD & Gordon L Fowler N, Flinn IW, Rule S, Chen R, Kwei L, Chu AD & Gordon L 'Abstract CT290: Ibrutinib-rituximab versus placebo-rituximab for first-line treatment of follicular lymphoma: PERSPECTIVE, a randomized phase 3 study' , DOI

Witzig TE, Casulo C, Cartron G, Ruan J, Rule S, Ando K, Burton C, Pinto A, Le Gouill S & Fowler NH Witzig TE, Casulo C, Cartron G, Ruan J, Rule S, Ando K, Burton C, Pinto A, Le Gouill S & Fowler NH 'Phase I/II study of durvalumab (anti–PD-L1 antibody) as monotherapy and in combination in patients with lymphoma or chronic lymphocytic leukemia' , DOI

Jurczak W, Rule S, Townsend W, Tucker D, Sarholz B, Scheele J, Gribben J & Zinzani PL Jurczak W, Rule S, Townsend W, Tucker D, Sarholz B, Scheele J, Gribben J & Zinzani PL 'Phase I/II, first in human trial with M7583, a Bruton’s tyrosine kinase inhibitor (BTKi), in patients with B cell malignancies' , DOI

Awada AH, Morschhauser F, Machiels J-P, Salles G, Rottey S, Rule S, Cunningham D, Peyrade F, Fruchart C & Arkenau H-T Awada AH, Morschhauser F, Machiels J-P, Salles G, Rottey S, Rule S, Cunningham D, Peyrade F, Fruchart C & Arkenau H-T 'PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors' , DOI

McCulloch R, Visco C, Frewin R, Tucker D, Kerr JP, Phillips N, Gandla J, Howard MR, Hodson A & Jack F McCulloch R, Visco C, Frewin R, Tucker D, Kerr JP, Phillips N, Gandla J, Howard MR, Hodson A & Jack F 'PS1255 EFFICACY OF R-BAC IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA POST BTK INHIBITOR THERAPY' , DOI

Wang M, Martin P, Phillips T, Goy A, Lossos IS, Rule SA, Hamadani M, Ghosh N, Reeder CB & Barnett E Wang M, Martin P, Phillips T, Goy A, Lossos IS, Rule SA, Hamadani M, Ghosh N, Reeder CB & Barnett E 'Effectiveness of Lenalidomide in Patients with Mantle Cell Lymphoma Who Relapsed/Progressed after or Were Refractory/Intolerant to Ibrutinib: The MCL-004 Study' , DOI

Lugtenburg P, Mous R, Clausen MR, Chamuleau MED, Johnson P, Linton K, Rule S, Oliveri RS, DeMarco D & Hiemstra IH Lugtenburg P, Mous R, Clausen MR, Chamuleau MED, Johnson P, Linton K, Rule S, Oliveri RS, DeMarco D & Hiemstra IH 'First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody®-CD3×CD20) in B-Cell Non-Hodgkin Lymphomas' , DOI

Le Gouill S, Davies A, Bouabdallah K, Chiron D & Rule S Le Gouill S, Davies A, Bouabdallah K, Chiron D & Rule S 'OAsis: An international phase I trial of obinutuzumab, venetoclax plus ibrutinib in relapsed/refractory mantle cell lymphoma' , DOI

McCulloch R, Rule S, Eyre TA, Goradia H, Bolam S, Creasey T, Tucker D, Furtado M, Miles O & Harrison S McCulloch R, Rule S, Eyre TA, Goradia H, Bolam S, Creasey T, Tucker D, Furtado M, Miles O & Harrison S 'Ibrutinib at First Relapse for Mantle Cell Lymphoma: A United Kingdom Real World Analysis of Outcomes in 169 Patients' , DOI

Le Gouill S, Morschhauser F, Bouabdallah K, Cartron G, Casasnovas O, Davies A, Chiron D & Rule S Le Gouill S, Morschhauser F, Bouabdallah K, Cartron G, Casasnovas O, Davies A, Chiron D & Rule S 'OBINUTUZUMAB PLUS IBRUTINIB IN RELAPSE/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS: FIRST RESULTS OF THE OASIS PHASE I TRIAL' , DOI

Owen R, McCarthy H, Rule S, D’Sa S, Thomas S, Tournilhac O, Forconi F, José Kersten M, Luigi Zinzani P & Iyengar S Owen R, McCarthy H, Rule S, D’Sa S, Thomas S, Tournilhac O, Forconi F, José Kersten M, Luigi Zinzani P & Iyengar S 'P1130: ACALABRUTINIB IN TREATMENT-NAIVE OR RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA: 5-YEAR FOLLOW-UP OF A PHASE 2, SINGLE-ARM STUDY' , DOI

Le Gouill S, Morschhauser F, Bouabdallah K, Cartron G, Casasnovas R-O, Milpied N-J, Gastinne T, Davies AJ, Herbaux C & Chiron D Le Gouill S, Morschhauser F, Bouabdallah K, Cartron G, Casasnovas R-O, Milpied N-J, Gastinne T, Davies AJ, Herbaux C & Chiron D 'Ibrutinib Plus Obinutuzumab and Venetoclax in Relapsed/Refractory Mantle Cells Lymphoma Patients, Results of the OASIS Phase I Clinical Trial' , DOI

Le Gouill S, Dlugosz-Danecka M, Rule S, Luigi Zinzani P, Goy A, Smith SD, Doorduijn JK, Panizo C, Shah B & Davies A Le Gouill S, Dlugosz-Danecka M, Rule S, Luigi Zinzani P, Goy A, Smith SD, Doorduijn JK, Panizo C, Shah B & Davies A 'P1131: POST HOC ANALYSIS OF PATIENTS WITH HIGHLY PROLIFERATIVE VARIANTS OF MANTLE CELL LYMPHOMA TREATED WITH ACALABRUTINIB' , DOI

Zinzani PL, Delwail V, Paneesha S, Rule S, Martin Garcia-Sancho A, Marin-Niebla A, Salles G, Sancho J-M, Vergote V & Zilioli VR Zinzani PL, Delwail V, Paneesha S, Rule S, Martin Garcia-Sancho A, Marin-Niebla A, Salles G, Sancho J-M, Vergote V & Zilioli VR 'Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205)' , DOI

Le Gouill S, Morschhauser F, Bouabdallah K, Cartron G, Casasnovas O, Gastinne T, Chevallier P, Rossi C, Tchernonog E & McCulloch R Le Gouill S, Morschhauser F, Bouabdallah K, Cartron G, Casasnovas O, Gastinne T, Chevallier P, Rossi C, Tchernonog E & McCulloch R 'Ibrutinib, Venetoclax Plus Obinutuzumab in Newly Diagnosed Mantle Cell Lymphoma Patients' , DOI

Tam CS, Rule S, Le Gouill S, Vitolo U, Tsao LC, Cavazos N, Beaupre DM & Wang ML Tam CS, Rule S, Le Gouill S, Vitolo U, Tsao LC, Cavazos N, Beaupre DM & Wang ML 'PHASE 3 STUDY OF IBRUTINIB IN COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (MCL)' , DOI

Rule S, Gois Barreto W, Briones J, Carella AM, Pocock C, Wendtner C-M, Zaja F, Robson S, Tschopp RR & Dreyling M Rule S, Gois Barreto W, Briones J, Carella AM, Pocock C, Wendtner C-M, Zaja F, Robson S, Tschopp RR & Dreyling M 'S101 EFFICACY AND SAFETY OF PROLONGED MAINTENANCE WITH SUBCUTANEOUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA: RESULTS OF THE PHASE III MABCUTE STUDY' , DOI

Bewicke-Copley F, Korfi K, Araf S, Kumar EA, Cummin TEC, Ashton-Key M, Barrans S, Van Hoppe S, Burton C & Elshiekh M Bewicke-Copley F, Korfi K, Araf S, Kumar EA, Cummin TEC, Ashton-Key M, Barrans S, Van Hoppe S, Burton C & Elshiekh M 'Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel' , DOI

Walter HS, Jayne S, Rule SA, Cartron G, Morschhauser F, Fegan C, Yang Y, Mitra S, Dyer MJS & Salles GA Walter HS, Jayne S, Rule SA, Cartron G, Morschhauser F, Fegan C, Yang Y, Mitra S, Dyer MJS & Salles GA 'Long-Term Follow-up with GS-4059, a Selective Irreversible BTK Inhibitor, in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia' , DOI

Lenz G, Balasubramanian S, Goldberg J, Rizo A, Schaffer M, Phelps C, Rule S & Dreyling MH Lenz G, Balasubramanian S, Goldberg J, Rizo A, Schaffer M, Phelps C, Rule S & Dreyling MH 'Sequence variants in patients with primary and acquired resistance to ibrutinib in the phase 3 MCL3001 (RAY) trial' , DOI

Villa D, Jiang A, Crosbie N, Rule S, McCulloch R, Visco C, Buege MJ, Kumar A, Bond D & Paludo J Villa D, Jiang A, Crosbie N, Rule S, McCulloch R, Visco C, Buege MJ, Kumar A, Bond D & Paludo J 'TIME TO SECOND LINE BRUTON TYROSINE KINASE THERAPY AND AGE AT ITS INITIATION ARE STRONGLY ASSOCIATED WITH SUBSEQUENT OVERALL SURVIVAL IN PATIENTS WITH FIRST RELAPSE OF MANTLE CELL LYMPHOMA' , DOI

Wang M, Barrientos JC, Furman RR, Mei M, Barr PM, Choi MY, de Vos S, Kallam A, Patel K & Rule S Wang M, Barrientos JC, Furman RR, Mei M, Barr PM, Choi MY, de Vos S, Kallam A, Patel K & Rule S 'VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma' , DOI

Rule S Rule S 'What is the Optimal Initial Management of the Younger Mantle Cell Lymphoma Patient?' Author Site , DOI

Phillips EH, Kirkwood AA, Lawrie A, Rule S, Patmore R, Pettengell R, Burton CH, Ardeshna KM, Montoto S & Paneesha S Phillips EH, Kirkwood AA, Lawrie A, Rule S, Patmore R, Pettengell R, Burton CH, Ardeshna KM, Montoto S & Paneesha S 'Low Rates of CNS Relapse in High Risk DLBCL Patients Treated with R-CODOX-M and R-IVAC: Results from a Phase 2 UK NCRI/Bloodwise Trial' , DOI

Trneny M, Lamy T, Walewski J, Belada D, Mayer J, Radford JA, Jurczak W, Morschhauser F, Alexeeva J & Rule SA Trneny M, Lamy T, Walewski J, Belada D, Mayer J, Radford JA, Jurczak W, Morschhauser F, Alexeeva J & Rule SA 'Outcomes Following Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma Patients at Risk of Bleeding Events Because of Multiple Comorbidities or Treatment: A Post-Hoc Subgroup Analysis of the SPRINT (MCL-002) Trial' , DOI

Rule S, Tucker D, Kalapur A, Sarholz B, Scheele J & Zinzani PL Rule S, Tucker D, Kalapur A, Sarholz B, Scheele J & Zinzani PL 'Phase I/II, first in human trial of the Bruton’s tyrosine kinase inhibitor (BTKi) M7583 in patients with B cell malignancies' , DOI

McCulloch R, Berrow M, Wainman B, Crosbie N, Pettitt A & Rule S McCulloch R, Berrow M, Wainman B, Crosbie N, Pettitt A & Rule S 'Population Based Observational Study Demonstrates Significant Increase in Watch-and-Wait for Newly Diagnosed Mantle Cell Lymphoma' , DOI

Salles GA, Morschhauser F, Cheson B, Rule SA, Fegan C, Guillaume C, Nelson C, Yang Y, Mitra S & Starodub A Salles GA, Morschhauser F, Cheson B, Rule SA, Fegan C, Guillaume C, Nelson C, Yang Y, Mitra S & Starodub A 'Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of GS-4059 in Combination with Idelalisib in Subjects with B-Cell Malignancies' , DOI

McCulloch R, Visco C, Frewin R, Phillips N, Eyre TA, Tucker D, Quaglia FM, McMillan A, Lambert J & Crosbie N McCulloch R, Visco C, Frewin R, Phillips N, Eyre TA, Tucker D, Quaglia FM, McMillan A, Lambert J & Crosbie N 'R-BAC Maintains High Response Rate in Mantle Cell Lymphoma Following Relapse on BTK Inhibitor Therapy' , DOI

Furman RR, Byrd JC, Owen RG, O'Brien SM, Brown JR, Hillmen P, Stephens DM, Patel P, Schwartz-Sagi L & Baek M Furman RR, Byrd JC, Owen RG, O'Brien SM, Brown JR, Hillmen P, Stephens DM, Patel P, Schwartz-Sagi L & Baek M 'Safety of acalabrutinib (Acala) monotherapy in hematologic malignancies: Pooled analysis from clinical trials' , DOI

Cramer P, Demirkan F, Fraser G, Pristupa A, Bartlett NL, Dilhuydy M-S, Loscertales J, Avigdor A, Rule SA & Samoilova O Cramer P, Demirkan F, Fraser G, Pristupa A, Bartlett NL, Dilhuydy M-S, Loscertales J, Avigdor A, Rule SA & Samoilova O 'Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial' , DOI

Danilov AV, Herbaux C, Dyer MJS, Hillmen P, Rule S, Kio EA, Huang X, Mitra S, Karlin L & Fegan C Danilov AV, Herbaux C, Dyer MJS, Hillmen P, Rule S, Kio EA, Huang X, Mitra S, Karlin L & Fegan C 'Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib Alone or in Combination with Idelalisib or Entospletinib in Patients with Previously Treated Chronic Lymphocytic Leukemia' , DOI

Salles G, Dyer MJS, Hodson DJ, Bouabdallah K, Ysebaert L, Cartron G, Davies AJ, Danilov AV, Fegan C & Kio EA Salles G, Dyer MJS, Hodson DJ, Bouabdallah K, Ysebaert L, Cartron G, Davies AJ, Danilov AV, Fegan C & Kio EA 'Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma' , DOI

Morschhauser F, Radford J, Ysebaert L, Spurgeon SE, Kio EA, Salles G, Huang X, Mitra S, Rule S & Dyer MJS Morschhauser F, Radford J, Ysebaert L, Spurgeon SE, Kio EA, Salles G, Huang X, Mitra S, Rule S & Dyer MJS 'Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Idelalisib in Patients with B-Cell Lymphoma' , DOI

Rule S, Barreto WG, Briones J, Carella AM, Casasnovas O, Pocock C, Wendtner CM, Zaja F, Robson S & Tschopp RR Rule S, Barreto WG, Briones J, Carella AM, Casasnovas O, Pocock C, Wendtner CM, Zaja F, Robson S & Tschopp RR 'EFFICACY AND SAFETY OF PROLONGED MAINTENANCE WITH SUBCUTANEOUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT NHL: RESULTS OF THE PHASE III MABCUTE STUDY' , DOI

Pettitt AR, Barrington S, Kalakonda N, Khan UT, Jackson R, Carruthers S, Oates M, Lin K, Ardeshna K & Eyre T Pettitt AR, Barrington S, Kalakonda N, Khan UT, Jackson R, Carruthers S, Oates M, Lin K, Ardeshna K & Eyre T 'NCRI PETREA TRIAL: A PHASE 3 EVALUATION OF PET-GUIDED, RESPONSE-ADAPTED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, ADVANCED-STAGE, HIGH-TUMOUR-BURDEN FOLLICULAR LYMPHOMA' , DOI

Visco C, Di Rocco A, Tisi MC, Morello L, Evangelista A, Zilioli VR, Rusconi C, Hohaus S, Sciarra R & Re A Visco C, Di Rocco A, Tisi MC, Morello L, Evangelista A, Zilioli VR, Rusconi C, Hohaus S, Sciarra R & Re A 'OUTCOMES IN FIRST RELAPSED-REFRACTORY YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: RESULTS FROM THE MANTLE-FIRST STUDY' , DOI

Rule S Rule S 'Mantle Cell Lymphoma' , DOI

Cramer P, Demirkan F, Fraser G, Pristupa A, Bartlett N, Dilhuydy M, Loscertales J, Avigdor A, Rule S & Samoilova O Cramer P, Demirkan F, Fraser G, Pristupa A, Bartlett N, Dilhuydy M, Loscertales J, Avigdor A, Rule S & Samoilova O 'IBRUTINIB INCREASES THE SYSTEMIC EXPOSURE OF RITUXIMAB: PHARMACOKINETIC RESULTS FROM THE HELIOS TRIAL' , DOI

Rule S, Jurczak W, Jerkeman M, Santucci Silva R, Rusconi C, Trneny M, Offner F, Caballero D, Joao C & Witzens-Harig M Rule S, Jurczak W, Jerkeman M, Santucci Silva R, Rusconi C, Trneny M, Offner F, Caballero D, Joao C & Witzens-Harig M 'IBRUTINIB VS TEMSIROLIMUS: THREE-YEAR FOLLOW-UP OF PATIENTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA FROM THE PHASE 3, INTERNATIONAL, RANDOMIZED, OPEN-LABEL RAY STUDY' , DOI

Rule S, Flinn IW, Fowler N, Chen R, Kwei L, Beaupre DM, Chu AD & Gordon LI Rule S, Flinn IW, Fowler N, Chen R, Kwei L, Beaupre DM, Chu AD & Gordon LI 'PHASE 3 STUDY OF IBRUTINIB IN COMBINATION WITH RITUXIMAB VERSUS PLACEBO IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH TREATMENT-NAÏVE FOLLICULAR LYMPHOMA (PERSPECTIVE)' , DOI

Profiles

Professor in Haematology (Research)

Peninsula Medical School (Faculty of Health)

Qualifications

Professional membership

Roles on external bodies

Research interests

Research groups